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ABSTRACT 
When wild animals are captured they often develop capture-related side-effects that 
may result in morbidity and mortality. During chemical capture of wild ungulates, 
capture-induced hyperthermia and opioid-induced respiratory depression occur 
commonly. Little is known about the mechanisms of capture-induced hyperthermia, 
and the effects of opioid drugs on respiratory function still need to be clarified. Also, 
current methods of reversing opioid-induced respiratory depression are inadequate. I 
therefore investigated the mechanisms and patterns of capture-induced hyperthermia, 
by continuously measuring body temperatures of impala during different capture 
procedures. I also investigated the effects of opioid drugs on respiratory function and 
pulmonary performance by examining the changes of cardiorespiratory variables 
before and during opioid immobilization of goats and impala. Concurrently, I 
investigated whether serotonergic ligands could be used to reverse the opioid-induced 
respiratory depression that occurred in these animals.  
 
I found stress to be the major factor associated with capture-induced hyperthermia, 
with exercise playing a minor role. I also found that environmental thermal conditions 
and the pharmacological effects of the capture drugs played no role in inducing 
capture-induced hyperthermia. I found that the opioid drug etorphine, which is 
commonly used to chemically capture wild animals, not only causes depression in 
respiratory rhythm and ventilation, but also a decrease in alveolar-arterial oxygen 
exchange. I demonstrated that serotonergic ligands with agonist effects at 5-HT1A and 
5-HT4 receptors partially reversed opioid-induced respiratory depression and hypoxia, 
predominantly by improving alveolar-arterial oxygen exchange, presumably by 
 IV 
increasing pulmonary perfusion and improving ventilation perfusion ratios, but also, 
in some cases, by improving ventilation.  
 
I advise that to limit the morbidity and mortality associated with capture-induced 
hyperthermia, procedures that cause the least stress should be used and animals should 
be exposed to stressors for the shortest time possible. The use of anxiolytic drugs to 
reduce stress may also be considered. If animals are captured by chemical 
immobilization with opioid drugs their respiratory function should be monitored 
closely. Counting breaths does not adequately monitor respiratory function and 
methods to assess carbon dioxide and oxygen levels in arterial blood should be used. 
If respiratory depression occurs, efforts to reverse this depression should not focus 
only on improving ventilation but also should aim at improving gas exchange in the 
lungs. Serotonergic ligands with agonist effects at 5-HT1A and 5-HT4 receptors could 
be used to achieve these aims. Although some of these ligands can cause arousal in 
immobilized animals, if they are administered with the opioid they enhance the 
induction of catatonic-immobilization, and their use in a dart may not only improve 
knock down times, thereby minimising stress and capture-induced hyperthermia, but 
they may also prevent opioid-induced respiratory depression.         
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Introduction 
 
 
 
 
 2 
The conservation of wildlife is important not only for maintaining the earth’s rich 
biodiversity, but also for the economies of many countries, as eco-tourism generates 
substantial revenue. An essential component of wildlife conservation and 
management is the capture and transport of wild animals. Techniques for capturing 
wild animals have improved substantially over the past few decades, reducing both 
animal mortalities and the costs of capture (McKenzie 1993).  However, an 
unacceptable number of animals still die or experience morbidity as a result of 
capture-related complications; mortalities as high as 43% have been reported in some 
capture operations (Knottenbelt 1990; Knox & Hattingh 1992; Murray et al. 1981). 
  
Any attempt at capturing a wild animal causes arousal in that animal (Knox 1992). 
That arousal induces the release of stress hormones (Hattingh et al. 1990), which 
changes the physiology of the animal’s body, preparing it for potential danger (Knox 
& Hattingh 1992; Meltzer & Kock 2006b). When animals are unable to escape the 
perceived danger, this arousal leads to an extreme psychological and physiological 
response which may result in stress, trauma, hyperthermia, capture myopathy, shock 
and ultimately death (Meltzer & Kock 2006b). To reduce arousal and the related 
adverse events, wild animals usually are captured by chemical immobilization with 
potent drug combinations. While these drugs sedate and calm animals, they also 
compromise the animal’s normal physiological function and may lead to bloat, 
vomiting or regurgitation, respiratory depression, hyperthermia, cardiovascular 
depression, shock and death (Meltzer & Kock 2006b).  
 
In this thesis I will address two of the adverse events most commonly associated with 
mortality during wildlife capture, namely capture-induced hyperthermia and opioid-
 3 
induced respiratory depression. This introductory chapter reviews the current 
knowledge of the mechanisms that result in, the consequences of, and the possible 
ways of reducing these side-effects, and poses the questions that are addressed in the 
thesis. 
 
1.1 Capture-induced hyperthermia  
1.1.1 Introduction 
Wild animals typically develop an acute hyperthermia when captured (Cheney & 
Hattingh 1987; Fuller et al. 2005; Gericke et al. 1978; Hofmeyr et al. 1973; Jessen et 
al. 1994; Kock et al. 1987a; Kock et al. 1987b; Martucci et al. 1992; Montané et al. 
2003; Montané et al. 2007). Although body temperature sometimes is measured and 
documented during capture operations, very little is said about the cause, significance 
and consequences of its elevation. Nevertheless, it has been proposed that capture-
induced hyperthermia may play a significant role in capture myopathy and acute death 
(Antognini et al. 1996; Cheney & Hattingh 1987; Gericke et al. 1978; Meltzer & 
Kock 2006b). However, the mechanisms involved in inducing this hyperthermia are 
not well understood and methods of preventing and treating capture-induced 
hyperthermia are based on intuition and anecdotal information, with little or no 
systematic investigation of whether they are beneficial.    
 
1.1.2 Possible mechanisms involved in capture-induced hyperthermia 
For hyperthermia to develop in an animal its heat production needs to exceed its heat 
loss. When this situation occurs heat is stored in the body and the magnitude of this 
heat storage is determined by the addition of the metabolic heat production to the rate 
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of heat transfer via evaporative, convective, radiative and conductive means between 
the animal and the environment (Jessen 2001; Willmer et al. 2005).  
 
Metabolic heat production increases via a number of mechanisms. An increase in 
resting metabolic rate can be achieved by increasing the metabolic activity of body 
organs and is usually brought about by either an increase in thyroid hormone activity 
or an increase in nutrient intake (Jansky 1995; Jessen 2001). The increase in resting 
metabolic rate is not usually associated with a sudden increase in heat production but 
rather with a slow increase over the long-term (Jessen 2001). Capture-induced 
hyperthermia, on the other hand, is associated with an acute precipitous increase in 
heat production and body temperature (Fuller et al. 2005; Jessen et al. 1994) and 
therefore it is unlikely that an elevation in resting metabolic rate via thyroid hormones 
and nutrient intake is involved.  
 
Acute increases in metabolic heat production can be brought about by other metabolic 
processes. These include shivering and non-shivering thermogenesis. Non-shivering 
thermogenesis occurs predominantly in brown adipose tissue and is brought about by 
the activation of sympathetic fibres which increases the rate of fatty acid oxidation via 
uncoupling proteins in the mitochondria (Jessen 2001; Willmer et al. 2005). This 
oxidative process bypasses the production of ATP and therefore energy released from 
this oxidation is not conserved, as would normally occur, but rather is dissipated into 
the body as heat (Jessen 2001). Although this process is highly effective at producing 
body heat, in some rodent species it can increase up to 500% of resting heat 
production (Guyton & Hall 1996), its role during capture-induced hyperthermia, 
particularly in large adult mammals, is still questionable. The reason is that the 
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general accepted dogma states that in larger species the presence of brown adipose 
tissue is restricted mainly to the perinatal period (Jessen 2001), with very few brown 
fat cells occurring in white fat tissue in adult life (Jansky & Jansky 2002). However, 
with the development of fluorodeoxyglucose positron emission tomography (FDG-
PET) significant amounts of brown adipose tissue have been indentified in adult 
humans (Nedergaard et al. 2007; Virtanen et al. 2009) and, this tissue appears to play 
a significant role in the control of body temperature and adiposity (Saito et al. 2009). 
However, these studies have only been done in humans and therefore the occurrence 
and metabolic significance of brown adipose tissue in other large adult mammals still 
needs to be determined. Shivering, on the other hand, may play a role in capture-
induced hyperthermia. Shivering is an involuntary tremor of the skeletal muscle that is 
used primarily to defend normal body temperature during cold exposure (Jessen 2001; 
Willmer et al. 2005). Two phases of shivering occur, the first being associated with 
continuous trains of action potentials to single motor units that result in an increase in 
muscle tension, and the second being associated with group discharges of motor units 
that result in oscillatory muscle movements (Jessen 2001). Although animals are 
usually normothermic before capture, and therefore not shivering, I have observed 
both muscle tension and oscillatory muscle movements in some animals during 
capture. Whether muscle tension and overt shivering always occur during capture and 
whether the changes are brought about by a thermal stimulus, or are centrally 
regulated in reaction to stress, needs to be determined.  
 
Acute increases in metabolic heat production also can be brought about by increasing 
energy turnover in the organs of the body. During capture, animals are often, but not 
always, highly active as they try to escape being captured (Burroughs & McKenzie 
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1993; Meltzer & Kock 2006b). This activity increases the work done by the skeletal 
muscles and also increases heat production of the muscles; up to 75% of the nutrient 
energy utilized during muscle contraction is released in the form of heat (Guyton & 
Hall 1997; Schönbaum & Lomax 1991d). The heat produced by muscle contraction 
during capture is not only limited to that of the skeletal muscles but also is produced 
by the heart and respiratory muscles as the activity of these muscles increases as the 
body’s demand for oxygen increases (Jessen 2001). Although animals often engage in 
high-intensity exercise during capture, when they are relatively inactive or in 
confinement during capture, they also display acute increases in body temperatures 
(Bakken et al. 1999). Therefore, unlike the current assumptions of game capture 
personnel that activity is the sole cause of capture-induced hyperthermia, activity does 
not appear to be essential for its development.     
 
An increase in heat production in animals can also be brought about by derangements 
in metabolism. Porcine Stress Syndrome is one of these derangements, where a 
precipitous rise in body temperature, severe lactacidosis, muscle pathology and acute 
death with the rapid onset of rigor are induced by natural stressors such as transport, 
high ambient temperature, exercise, fighting, copulation and parturition (Patterson & 
Allen 1972). Although this syndrome is described in pigs, many other species 
including humans, horses, zebra and a number of antelope and bird species develop 
the same clinical symptoms after extreme bouts of exercise. Because of these similar 
symptoms Porcine Stress Syndrome has been equated to the cause of exertional 
myopathy in man and horses, and capture myopathy in wild animals (Mitchell & 
Heffron 1982). However, the distinguishing feature of Porcine Stress Syndrome, 
compared to exertional myopathy and capture myopathy, is that pigs that develop 
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Porcine Stress Syndrome are stress-susceptible and develop aberrant metabolic 
changes even after exposure to minor stressors. In addition, these pigs have a genetic 
deficit which also predisposes them to develop drug-induced malignant hyperthermia 
(Mitchell & Heffron 1980).  
 
Drug-induced malignant hyperthermia is a hereditary membrane disorder which is 
brought about mainly by anaesthetic agents and results in a hypercatabolic 
derangement in metabolism (Ali et al. 2003; Schönbaum & Lomax 1991a). The 
pathophysiology of malignant hyperthermia involves an uncontrolled release of 
cytoplasmic free calcium from the sarcoplasmic reticulum which leads to the 
activation of energy-liberating biochemical pathways and results in a precipitous rise 
in body temperature, hyperkalaemia and acidosis (Ali et al. 2003). Malignant 
hyperthermia has been reported in humans, pigs, dogs, cats, horses and cattle 
(Schönbaum & Lomax 1991a). It is induced predominantly by halogenated volatile 
anaesthetics like halothane, isoflurane and enflurane, and depolarizing muscle 
relaxants like succinylcholine (Ali et al. 2003); other drugs like local anaesthetics and 
caffeine also may trigger its occurrence (Schönbaum & Lomax 1991a). Drug-induced 
malignant hyperthermia has been shown to play no role in the development of capture 
myopathy (Antognini et al. 1996) and no reports have been documented during 
wildlife capture. Indeed, the drugs that induce malignant hyperthermia are used rarely 
in wildlife capture, with the exception of succinylcholine which is used to capture 
crocodiles and cull elephants (Burroughs et al. 2006), both of which don’t show 
malignant hyperthermia. Therefore a role for drug-induced malignant hyperthermia in 
capture-induced hyperthermia is unlikely.  
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However, it is possible that drugs that are used in capture may cause other 
derangements in metabolism that increase heat production. Neuroleptic drugs, like 
azaperone, haloperidol, zuclopenthixol acetate and perphenazine enanthate are used 
extensively as tranquilizers during capture and the housing of wildlife (Meltzer & 
Kock 2006a; Swan 1993a). These drugs may cause neuroleptic malignant syndrome, a 
syndrome that has been documented mainly in humans and is associated with a drug-
induced hyperthermia. Its pathogenesis is unlike that of drug-induced malignant 
hyperthermia but it causes a similar hypermetabolic state (Nisijima et al. 2007; 
Ohnishi 1994).  Although there is no documented evidence, it is possible that 
neuroleptic malignant syndrome may contribute to capture-induced hyperthermia, but 
only when neuroleptic drugs are used; neuroleptics are not always used during capture. 
In addition, neuroleptics affect thermoregulation through several mechanisms, 
including anti-adrenergic effects, inhibition of sweating, and central dopamine 
antagonism, which disrupt the thermoregulatory set-point causing thermal lability 
(Fick 2007; Fick et al. 2006). This disruption in thermoregulation would alter the rate 
of heat transfer between the animal and the environment and, under high 
environmental heat loads, also may contribute to an increase in an animal’s body 
temperature during capture.  
 
A drug-induced disruption in thermoregulation is not only limited to the neuroleptic 
drugs but also may occur with the sedatives and immobilizing agents that are used 
during capture. α2-agonists are drugs that are used commonly as sedatives during 
chemical capture. These drugs induce thermal lability (Jalanka & Roeken 1990; 
Maskrey et al. 1970) by affecting the central noradrenergic mechanisms that control 
body temperature regulation (Cremer & Bligh 1969). The opioids, which are used as 
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immobilizing agents in the majority of herbivore species, also alter thermoregulation. 
Their effects on thermoregulation are complex and depend on either the drug, the dose, 
the route of administration, the species, ambient conditions and the behavioural state 
of an animal (Schönbaum & Lomax 1991c). Meltzer and Kock (2006b) proposed that 
during chemical capture the adrenergic effects of opioid drugs increase metabolic rate 
and, hence, heat production. Although the adrenergic effects of opioid drugs have 
been demonstrated in rats given etorphine (Roquebert & Delgoulet 1988), these 
effects have not been linked to body temperature changes, so the effect of the opioid 
drugs on capture-induced hyperthermia is unclear.  
 
Apart from the possible role of capture drugs in capture-induced hyperthermia, it has 
also been proposed that environmental conditions prevailing during capture influence 
body temperatures (Ebedes et al. 1996; McKenzie 1993). From these proposals, it has 
become accepted in the game capture industry that animals should not be caught when 
ambient temperatures exceed 25˚C, and therefore that capture operations should be 
restricted to the early mornings and late afternoons (Ebedes et al. 1996; Kock et al. 
2006; McKenzie 1993). The primary objective of these recommendations is to ensure 
that hyperthermic animals are able to dissipate body heat to the environment after 
capture (Meltzer & Kock 2006b). However, these recommendations also have led to 
the assumption that animals will become hyperthermic if they are captured on hot 
days (Ebedes et al. 1996; Wenger et al. 2007). This assumption may well be true if 
capture-induced hyperthermia was a passive hyperthermia brought on by high 
environmental heat loads, but it is unlikely as many animals that are captured on cold 
days also develop capture-induced hyperthermia (Montané et al. 2003; Montané et al. 
2007). 
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An increase in metabolic heat production during capture can also be brought about by 
changes in circulating hormones. A number of hormones such as adrenaline, 
noradrenaline, cortisol, glucagon and insulin enhance the activity of metabolic 
pathways and therefore are thermogenic (Jansky 1995; Schönbaum & Lomax 1991d). 
However, the role of hormonal thermogenesis in capture-induced hyperthermia is not 
known. What is known is that capture causes the release of some of these hormones, 
but their conventional role is believed to be related to a reaction to stress rather than to 
thermogenesis (Hattingh & Petty 1992).  
 
Finally, stress, itself, may stimulate an increase in heat production and play a role in 
the generation of capture-induced hyperthermia. Although it has been proposed that 
stress plays a role in capture-induced hyperthermia (Burroughs & McKenzie 1993; 
Meltzer & Kock 2006b; Montané et al. 2003; Montané et al. 2007), especially in 
captures that result in capture myopathy (Gericke et al. 1978; Harthoorn 1976; 
Mitchell & Heffron 1982), it is uncertain how important its role is. Although stress is 
difficult to quantify, its occurrence can be identified by measuring the body’s 
behavioural, biochemical and cellular reactions after exposure to a stressor (Hattingh 
1988b; Möstl & Palme 2002). By using these measures, the occurrence of stress has 
been identified in wild animals in different capture procedures and in a wide variety 
of species (Cheney & Hattingh 1987; Ganhao et al. 1989; Ganhao et al. 1988; 
Hattingh 1988a; Hattingh & Petty 1992; Knox & Hattingh 1992; Knox & Zeller 1993; 
Kock et al. 1987a; Kock et al. 1987b; Martucci et al. 1992; Morton et al. 1995; Read 
et al. 2000). Acute stress results in a centrally mediated response, through the 
activation of the hypothalamic-pituitary-adrenal axis and the sympatho-adrenal-
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medullary system (Henry 1992), which alters an animal’s physiology in preparation 
for a fight or flight response (Meltzer & Kock 2006b).    
 
Activation of the hypothalamic-pituitary-adrenal axis results in the enhanced secretion 
of corticotropin releasing hormone, adrenocorticotrophic hormone and 
glucocorticoids (Guyton & Hall 1997). Corticotropin releasing hormone has 
thermogenic effects, but these effects are dependent on sympathetic activation of 
brown adipose tissue (Olivier et al. 2003; Rothwell 1990). The thermogenic effects of 
glucocorticoids also appear to be dependent on the metabolic activation of brown 
adipose tissue (Hampl et al. 2006). Thus it is unlikely that glucocorticoids and 
corticotropin releasing hormone increase body temperature of large adult animals 
during capture. On the other hand, the activation of the sympatho-adrenal-medullary 
system with the subsequent release of adrenaline and nor-adrenaline (Guyton & Hall 
1997) may increase the body temperature of animals during capture. Normal 
sympathetic stimulation and circulating adrenaline and nor-adrenaline decreases heat 
loss from the body by causing vasoconstriction and, it also increases the rate of 
cellular metabolism, but this increase usually increases the rate of heat production by 
only 10 to 15% (Guyton & Hall 1996). This effect is important during cold exposure 
in both small and large mammals as it helps maintain normal body temperature 
(Jansky & Jansky 2002). However, the infusion of high doses of exogenous 
catecholamines can increase metabolic rate by as much as 45% of basal metabolic rate 
in adult humans and sheep (Graham & Christopherson 1981; Lesna et al. 1999). 
Whether high surges of endogenous catecholamines, particularly those that occur 
during capture (Hattingh et al. 1988), can produce a similar effect is not known. Even 
if it could, this may not increase body temperature because Graham & Christopherson 
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(1981) showed that even though high doses of exogenous catecholamines increased 
sheep’s metabolic rate by 45% it did not significantly increase their body temperature.  
 
The rise in body temperature that is induced by stress is termed “stress-induced 
hyperthermia”. Stress-induced hyperthermia is mediated by the autonomic nervous 
system and occurs prior to and during exposure to stressors like noise, heat, handling, 
novelty or pain (Olivier et al. 2003). Stress-induced hyperthermia occurs concurrently 
with the endocrine stress response, which is brought about by the stimulation of the 
hypothalamic-pituitary-adrenal axis and the sympatho-adreno-medullary system 
(Groenink et al. 1994). However, it does not appear that this hyperthermia results 
from the direct effect of hypothalamic-pituitary-adrenal axis stimulation, because 
stress-induced hyperthermia can be reduced even while the hypothalamic-pituitary-
adrenal axis remains activated (Olivier et al. 2003). Because of these and other 
experimental findings it has been suggested that stress-induced hyperthermia is a 
psychogenic fever that is centrally regulated and brought about by an elevation in the 
thermoregulatory “set point”, similar to that of fever (Briese & Cabanac 1991). This 
mechanism was proposed because cyclooxygenase inhibitors, which attenuate fever, 
have been shown to partially attenuate stress-induced hyperthermia (Michel et al. 
2003; Morimoto et al. 1991). However, the view that stress-induced hyperthermia is a 
psychogenic fever has been strongly contested and, recently, Vinkers et al. (2009) 
have shown unequivocally (see example in Fig. 1) that stress-induced hyperthermia 
and infection-induced fever are two distinct processes mediated largely by different 
neurobiological mechanisms. However, their findings still cannot explain why 
cyclooxygenase inhibitors partially attenuate the r
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Figure 1. Effects of (A) diazepam (0-4mg.kg-1, IP) and (B) aspirin (0-300mg.kg-1, 
PO) on stress-induced hyperthermia in C57 mice (n=11). Note the stress-induced 
hyperthermia induced by the stress of handling at injection (60 min), and that of being 
placed in a new cage (120 min). The anxiolytic diazepam attenuates the stress-induced 
hyperthermia but the cyclooxygenase inhibitor aspirin does not. **: p<0.01, ***: 
p<0.001. (Taken from Figure 1. Vinkers CH, Groenink L, van Bogaert MJV, 
Westphal KGC, CJ Kalkman CJ, van Oorschot R, Oosting RS, Olivier B, and Korte 
SM (2009) Physiology & Behavior 98: 37-43.) 
 
 14 
temperature in some models of stress in rats. Oka et al. (2001) propose that stress-
induced hyperthermia, or as they term it “psychological stress-induced rise in core 
temperature” can be induced by two different mechanisms, a prostaglandin E2-
dependent mechanism (psychogenic fever) and a prostaglandin E2-independent 
mechanism (anticipatory anxiety-induced rise in core temperature). Their proposal 
explains why cyclooxygenase inhibitors partially attenuate the rise in body 
temperature in some models of stress like “open-field stress”, but not in others like 
“anticipatory or anxiety stress” (Oka et al. 2001). However, any model of 
psychological stress will induce some form of anxiety and therefore it seems plausible 
that the main cause of the rise in body temperature, irrespective of which stress model 
is used, will be because of prostaglandin E2-independent mechanisms.  
 
It has been proposed that stress-induced hyperthermia is ubiquitous because it is 
present in virtually any mammal that has been tested so far (Bouwknecht et al. 2007; 
Vinkers et al. 2008). In rats and mice it has been studied extensively and its 
occurrence in different stress models has allowed it to be used as a measure of stress 
and anxiety in behavioural and pharmacological studies (Bouwknecht et al. 2007; 
Olivier et al. 2003; Vinkers et al. 2008). It has been speculated that stress-induced 
hyperthermia is a component of capture-induced hyperthermia in wild animals 
(Bakken et al. 1999; Burroughs & McKenzie 1993; Montané et al. 2003; Montané et 
al. 2007), however, no studies have validated this theory. Although stress-induced 
hyperthermia has been the subject of many studies it is still unclear as to how it is 
mediated (Oka et al. 2001) and, like all the other potential causes of hyperthermia, it 
is uncertain as to what role it may play in capture-induced hyperthermia.   
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Several different mechanisms may be involved in capture-induced hyperthermia, but 
few have been tested (see Table 1 for a summary of the potential causes of capture-
induced hyperthermia). To successfully prevent or treat capture-induced hyperthermia 
it is essential to understand how it is caused and the mechanisms involved in the 
generation or retention of body heat. Systematic studies using different capture 
procedures which involve the use of capture drugs, capture without drugs, capture 
with varying environmental conditions and capture with varying levels of exercise and 
stress, are required to elucidate these mechanisms.  
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Table 1. Summary of the potential causes of heat production that may result in capture-induced hyperthermia 
Potential cause of 
heat production 
 Likelihood  Tested  Reference 
Non-shivering 
thermogenesis  
Possible – In humans there is growing 
evidence that metabolically active 
brown adipose tissue occurs in adult 
life 
 
Untested – requires clarification 
of the occurrence and metabolic 
significance of brown adipose 
tissue in other large adult 
mammalian species 
 
(Nedergaard 
et al. 2007; 
Saito et al. 
2009; 
Virtanen et 
al. 2009) 
       
Shivering   
Possible – muscle tension and 
shivering have been observed during 
capture 
 Untested  
(Jessen 
2001; 
Willmer et 
al. 2005) 
       
Exercise metabolism  
Possible – exercise will increase body 
temperature but capture-induced 
hyperthermia can occur in inactive 
animals 
 Untested  (Bakken et 
al. 1999) 
       
Drug-induced 
malignant 
hyperthermia 
 
Unlikely – capture-induced 
hyperthermia occurs irrespective of 
whether drugs are used or not 
 Tested  (Antognini et 
al. 1996) 
       
Neuroleptic malignant 
syndrome  
Unlikely - capture-induced 
hyperthermia occurs irrespective of 
whether neuroleptic drugs are used or 
not 
 Untested  
(Nisijima et 
al. 2007; 
Ohnishi 
1994) 
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Potential cause of 
heat 
 Likelihood  Tested  Reference 
Adrenergic effects of 
opioid drugs  
Possible – opioid drugs have been 
shown to have adrenergic effects, but 
capture-induced hyperthermia occurs 
even when no opioids are used 
 
Untested - requires 
clarification, there is no 
evidence that the adrenergic 
effects of the opioids cause 
hyperthermia 
 
(Schönbaum 
& Lomax 
1991b) 
       
Environmental  Unlikely – capture hyperthermia can 
occur in cold environments  Untested  
(Montané et 
al. 2003; 
Montané et 
al. 2007) 
       
Hormonal metabolism  
Possible – a number of hormones, 
particularly stress hormones are 
known to be thermogenic 
 Untested  (Jansky 1995) 
       
Stress  
Likely – stress-induced hyperthermia 
appears to be ubiquitous in mammals 
exposed to stressors 
 Untested  
(Bouwknecht 
et al. 2007; 
Vinkers et al. 
2008) 
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1.2 Opioid-induced respiratory depression 
1.2.1 Introduction 
The therapeutic uses of the opioids include the alleviation of pain and coughing, 
induction and maintenance of anaesthesia, antidiarrhoeal and chemical immobilization 
of wildlife (Bowdle 1988; Meltzer & Kock 2006a; Rang et al. 2003; Swan 1993b). 
However, their benefits can be produced at a cost to breathing and tissue oxygenation, 
which can lead to irreversible tissue damage and death (Bowdle 1988; Eilers & 
Schumacher 2004). These effects are always important as they may contribute 
significantly to mortality when wild animals are chemically captured (Haigh 1990; 
Meltzer & Kock 2006b).  
 
The opioids that are used to chemically immobilize wildlife are derived from 
alkaloids found in opium or synthetic substances based on morphine’s structure 
(Meltzer & Kock 2006b). These opioids are highly potent; etorphine has an analgesic 
potency up to 10000 times that of morphine (Swan 1993a). Because of these high 
potencies and their intrinsic activities, opioids that are used to chemically capture 
wildlife may cause respiratory depression. In some species, like canids and primates, 
opioids tend to cause severe central nervous system depression, while in others, like 
porcids, felids and equids, they tend to cause excitement (Hannon & Bossone 1991; 
Swan 1993b). Therefore, opioids are used to immobilize and capture only certain 
species which mostly come from the orders of perissodactyla, artiodactyla and 
proboscidae (see Table 2 for a summary of the opioid drugs commonly used to 
immobilize wildlife). Even within these species the opioids have varying effects, with 
some species being more prone to developing respiratory depression than others. 
 19 
Those species that are more susceptible to respiratory depression include giraffe, 
hippopotamus, waterbuck, impala and white rhino (McKenzie 1993; Meltzer & Kock 
2006b). There also are inherent differences to the pharmacological effects of the 
opioids amongst individuals within a species and thus some individuals may be more 
susceptible to developing respiratory depression than others (Ballanyi et al. 1997). 
However, when any animal is chemically captured from the wild, it is not possible to 
accurately predict its mass and therefore drug overdosing and adverse events like 
respiratory depression can occur in any species or individual irrespective of their 
susceptibilities. Therefore it is important to understand the effects of opioids on 
respiratory function and determine how to reverse opioid-induced respiratory 
depression, without reversing the immobilizing properties of the opioids, during 
chemical capture of wild animals. 
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Table 2. Summary of opioid drugs used to chemically capture wildlife (Kock et al. 2006; McKenzie 1993) 
Opioid generic name  Opioid trade name 
and distributor 
 Species immobilized  Comments 
Etorphine 
hydrochloride  
M99, Norvatis, RSA  
or 
 Captivon 98, Wildlife 
Pharmaceuticals, RSA 
 
From the orders of 
perissodactyla, 
artiodactyla and 
proboscidae 
 
Most commonly used opioid 
agonist in Southern Africa 
       
Fentanyl   Sublimase, Janssen Animal Health, RSA  
Mainly used in small 
artiodactyla, also used in 
canids e.g. wild dogs 
 
Opioid agonist,  
1/15 the potency of etorphine. 
Ineffective in equids  
       
Carfentanil  Wildnil, Wildlife Pharmaceuticals, USA  As for etorphine  
Opioid agonist  
Not available in Southern Africa 
More potent than etorphine, faster 
action and longer duration 
Not very effective in equids 
       
Thiofentanil  A3080, Wildlife Pharmaceuticals, RSA  As for etorphine  
Opioid agonist  
Potency similar to etorphine but 
faster action and shorter duration 
Ineffective in equids 
       
Butorphanol  tartrate  
Formulated to obtain 
high enough 
concentrations 
 
 
Experimental use in a 
number of species 
including the carnivores  
 
Opioid agonist-antagonist 
Does not cause full immobilization 
Less respiratory depressant effects  
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1.2.2 Control of respiration and the mechanisms that are involved in opioid-
induced respiratory depression 
Breathing is controlled by a neuronal network that is found in the lower brainstem. 
This neuronal network innervates spinal motoneurones causing periodic contractions 
of respiratory muscles, which ventilate the lungs (Richter & Spyer 2001). During 
rapid shallow breathing contraction of respiratory muscles and the flow of air into and 
out of the lungs is generated by inspiratory and post-inspiratory (stage 1 expiration) 
neuronal phases. During deeper breathing these phases are supplemented by a third 
active expiratory (stage 2 expiration) phase (Ramirez & Richter 1996; Richter et al. 
2000; Richter & Spyer 2001). The inspiratory neuronal phase corresponds to the 
contraction of inspiratory muscles, the post-inspiratory phase to passive exhalation 
where inspiratory muscles cease to contract and upper airway adductor muscles relax, 
and the active expiratory phase to the period where expiratory muscles contract 
(Bonham 1995; Haji et al. 2000).  
 
The neuronal respiratory network in the brainstem is composed of groups of neurones 
that control and regulate the cycling of the respiratory phases (See Fig. 2). These 
groups of neurones are arranged bilaterally in the brainstem and consist of a dorsal 
and ventral respiratory group and pontine respiratory centres (Bonham 1995). The 
respiratory groups contain different types of respiratory neurones that discharge at 
different times throughout the respiratory cycle (Bonham 1995). Respiratory activity 
is controlled by synaptic interactions between the different types of respiratory 
neurones, and these interactions activate or inhibit the phases of the respiratory cycle 
to generate respiratory rhythm (Richter & Spyer 2001). The ventral 
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Figure 2. Respiratory control centres in the brainstem 
(Taken from Figure 13-33. Sherwood L (2001, 4th Edition), Brooks/Cole Thomson 
Learning, Pacific Grove, USA, pp. 766)(Sherwood 2001) 
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respiratory group contains all of the different types of respiratory neurones and 
therefore is essential for rhythm generation (Bonham 1995; Richter & Spyer 2001). 
The ventral respiratory group has been divided into caudal, intermediate, rostral, pre-
Bötzinger, and Bötzinger complexes and the parafacial group. Of these the pre-
Bötzinger complex has been identified to be the main area that generates respiratory 
rhythm as it contains a kernel of respiratory neurones that have intrinsic bursting 
properties necessary for respiratory rhythm generation (Schwarzacher et al. 1995; 
Smith et al. 1991). However, there is currently debate about whether the pre-
Bötzinger complex is the primary respiratory rhythm generator, or whether the 
parafacial respiratory group determines the rhythm of the neurones in the pre-
Bötzinger complex (Onimaru et al. 2006). Despite this controversy it appears that the 
pre-Bötzinger complex plays a major role in respiratory rhythm generation (Onimaru 
et al. 2006; Peña & García 2006) and emerging evidence shows that the pre-Bötzinger 
complex and the parafacial respiratory group act as a coupled oscillator with 
modulating influences from the pons (Pattinson 2008). 
 
Respiratory rhythm also is modulated by many sensory inputs that are external to the 
known respiratory neuronal groups. These inputs help regulate respiratory pattern 
generation and the volume and frequency of breathing (Gray et al. 1999; Ramirez & 
Richter 1996). The effects of these sensory inputs, and the connectivity of the 
neurones of the respiratory network, occur through a number of neurotransmitters that 
activate specific receptors. The principal neurotransmitters in the respiratory network 
are glutamate, GABA and glycine (Bonham 1995; Haji et al. 2000; Richter et al. 
1997). Serotonin, catecholamines, acetylcholine, substance P, somatostatin, 
cholecystokinin, and endogenous opioids play a secondary neuromodulatory role 
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(Bonham 1995; Haji et al. 2000; Richter et al. 1997). The role of many of these 
neurotransmitters in respiratory control is well known, but it is not clear what role 
endogenous opioids play. It appears that they are not involved in the generation of 
normal respiration (Bonham 1995), but rather that they play a role during acute stress 
and in abnormal respiratory states like sleep apnoea and hypoxic apnoea. The role of 
endogenous opioids during these events has been proposed to be neuroprotective as 
they reduce excitotoxicity of neurones (Richter et al. 2000; Shook et al. 1990). 
Although endogenous opioids appear to play no role in normal respiration, opioid 
receptors are highly expressed throughout the respiratory network (Lonergan et al. 
2003a; Pattinson 2008) and are particularly concentrated in the pre-Bötzinger 
complex (Gray et al. 1999; Manzke et al. 2003).  
 
Opioid drugs cause respiratory depression mainly through their activation of opioid 
receptors that occur in respiratory neurones (McCrimmon & Alheid 2003; Shook et al. 
1990). Different opioid drugs do not cause equivalent respiratory depressive effects as 
their effects on respiratory function are dependent on which opioid receptors they 
activate. The activation of mu(µ)-opioid receptors, in particular µ2 receptors, causes 
respiratory depression (Haji et al. 2000; Shook et al. 1990). There is also evidence that 
activation of both delta (δ)- and kappa (κ)-opioid receptors also causes respiratory 
depression (Ballanyi et al. 1997; Bowdle 1988; Lonergan et al. 2003b; Takeda et al. 
2001), but the main depressant effects of opioids appear to be caused by the activation 
of µ2-opioid receptors (Haji et al. 2000).  
 
The activation of opioid receptors results in a number of effects that cause respiratory 
depression. The neurones in the pre-Bötzinger complex appear to be the most 
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sensitive to µ-opioid agonists and therefore the most important of these effects is a 
disturbance in respiratory rhythm (Lalley 2003; Pattinson 2008). Opioids also disturb 
respiratory rhythm by activating respiratory neurones in the pons and also reduce the 
ability of the ventral respiratory group neurones to react to the chemoreceptor 
response to hypercapnia and hypoxia (Lalley 2008; McCrimmon & Alheid 2003; 
Pattinson 2008; Santiago & Edelman 1985; Shook et al. 1990). Opioids also depress 
the neurones that regulate tidal volumes, and thus may decrease the depth of breathing 
(Lalley 2003; Lalley 2008). They also inhibit the actions of vagal motorneurones 
which promote dilation of vocal folds (Lalley 2003), thereby causes an increase in 
upper airway resistance (Lalley 2008). In addition, opioids cause catatonia (Haveman 
& Kuschinsky 1982), which results in generalised muscle rigidity and a decrease in 
the chest wall compliance (Chen et al. 1996). They also increase the resistance to 
chest wall expansion by tonically activating expiratory neurones during inspiration 
(Lalley 2003; Lalley 2008). The respiratory depressant effects of the opioids are not 
limited to their effects on respiratory neurones in the central neuronal network. 
Opioids have a direct action on carotid bodies, which causes a decrease in 
chemoreceptor discharge and thus further depresses the response to hypoxia and 
hypercapnia (Pattinson 2008; Santiago & Edelman 1985). Opioids also activate 
pulmonary J receptors which may cause opioid-induced apnoea (Bowdle 1998; 
McKenzie 1993; Santiago & Edelman 1985; Shook et al. 1990). The combination of 
all these effects will lead to a decrease in respiratory pump action and cause 
hypoventilation with its associated pathophysiological effects.  
 
The effects of the opioids, on both the central and peripheral neurones, therefore play 
a major role in decreasing pulmonary ventilation. However, the respiratory depressant 
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effects of the opioids are not limited to just the effects on ventilation; opioids also 
have marked effects on the cardiovascular system that may cause a decrease in the 
perfusion both of the lungs and other organs thus decreasing oxygen delivery to 
tissues. The effects of opioids on the cardiovascular system are complex and 
dependent on the opioid and dose used (Bowdle 1998). However, the opioids used 
during chemical immobilization of wildlife generally cause systemic and pulmonary 
vasoconstriction (Haigh 1990; Heard et al. 1990; Heard et al. 1996; Santiago & 
Edelman 1985) by either activating the sympathetic nervous system (Hannon & 
Bossone 1991; Heard et al. 1990; Heard et al. 1996; Roquebert & Delgoulet 1988) or 
possibly by causing the release of histamine (Hakim et al. 1992; Mather 1994). These 
vascular effects would result in a decrease in blood perfusion of body tissues, and 
would cause ventilation perfusion mismatching or shunting of blood in the lungs, and 
a decrease in oxygen diffusion across the alveolar membrane (Nunn 1993). Few 
studies have assessed pulmonary blood shunting and oxygen diffusion during opioid 
immobilization of animals. Two of the studies that have done so, have shown that 
opioid immobilization causes a decrease in oxygen diffusion in immobilized 
rhinoceros (Wenger et al. 2007) and elephant (Still et al. 1996). However, in another 
study in goats (Buss & Meltzer 2001) (Buss 2000), the authors argue that opioid 
immobilization did not result in pulmonary blood shunting. Their claims, however, 
appear to be erroneous as they calculated shunt fraction based on the incorrect 
assumption that the partial pressure of oxygen in the alveoli is equal to that of the 
partial pressure of oxygen in end capillary pulmonary vessels.  
 
Although much is known about the neurological control of respiration, and the effects 
of opioids on this control, a better and more integrative understanding of the effects of 
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the opioids on cardio-respiratory control and function is needed, especially if more 
effective treatments for opioid-induced respiratory depression are to be established.   
 
1.2.3 Reduction of opioid-induced respiratory depression 
Many different pharmacological agents have been used in attempts to reduce or 
reverse the respiratory depressant effects of the opioids in both man and other animals 
(see table 3 for summary of receptor and respiratory activity of ligands recently 
investigated to reverse opioid-induced respiratory depression). Opioid receptor 
antagonists, or partial opioid receptor antagonists, like naloxone, nalorphine, 
butorphanol, nalbuphine, diprenophine and naltrexone have relieved respiratory 
depression successfully, but their major drawback is that they cause unwanted side-
effects by blocking analgesia, causing cardiovascular instability, and reversing 
anaesthesia and chemical immobilization (Bowdle 1988; Swan 1993b). Analeptic 
drugs cause widespread central nervous system stimulation which results in increased 
ventilation (Bowdle 1988). Some of the analeptics like bemegride, nikethamide and 
picrotoxin, which have been used in the past, have lost favour because of their 
convulsant effects (Swan 1993b). One analeptic still used is doxapram. Unlike other 
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Table 3. Serotonergic and dopaminergic ligands investigated for reversal of opioid-induced respiratory depression 
Ligand  Dose  Species  Respiratory effect  Known receptor activity   References 
        Primary Secondary   
            
BIMU-8  1-2 
mg.kg-1  Rats  
increased phrenic nerve 
activity and respiratory 
minute volume 
 
 
5-HT4(a) 
agonist 
 
5-HT3 
antagonist  
(Manzke 2004; 
Manzke et al. 
2003; Wang et al. 
2007) 
            
Mosapride 
  
15 mg 
 
100 
mg.kg-1 
 
 
Humans 
 
 
Rats 
 
no effect on respiratory 
minute volume  
 
 
5-HT4 agonist 
 
 
 
(Lötsch et al. 
2005) 
            
8-OH-DPAT 
  
10-100 
µg.kg-1 
 
 
Rats 
 restored respiratory rate 
and increased 
respiratory minute 
volume 
 
5-HT1A agonist 
 
5-HT7 
agonist 
 
 (Manzke 2004; 
Sahibzada et al. 
2000; Wang et al. 
2007) 
            
Buspirone 
 
50 
µg.kg-1 
 
60 mg 
 
Rats 
 
 
Humans 
  
restored respiratory rate 
 
 
no effect on respiratory 
minute volume 
 
5-HT1A agonist 
dopamine 
receptor 
dependant 
effects 
 
(Sahibzada et al. 
2000) 
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Ligand  Dose   Species  Respiratory effect  Known receptor activity   References 
        Primary Secondary   
            
α-methyl-5-
HT  
100 
µg.kg-1  Rat  
no effect on respiratory 
neuronal activity  5-HT2A   (Manzke 2004) 
            
BW 723C86  1 
mg.kg-1  Rat  
no effect on respiratory 
neuronal activity  5-HT2B   (Manzke 2004) 
            
6-chloro APB  3  
mg.kg-1  Cat  
increased respiratory 
rate and depth and 
improved HbO2 and 
ETCO2 
 
D1-dopamine 
agonist   (Lalley 2005a) 
            
Dihydrexidine  1  
mg.kg-1  Cat  
increased respiratory 
rate and depth and 
improved HbO2 and 
ETCO2 
 
D1-dopamine 
agonist   (Lalley 2005a) 
ETCO2 – end tidal carbon dioxide, HbO2 – Oxygen saturation of haemoglobin 
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analeptics, doxapram has a wide safety margin; its convulsant dose is 70-75 times the dose that 
stimulates respiratory activity (Swan 1993b). Doxapram not only causes central nervous system 
stimulation but it also stimulates peripheral chemoreceptors (Haji et al. 2000; Nishino et al. 1982; 
Swan 1993b). Its use, especially during chemical immobilization, is limited by its short duration 
of effect (Swan 1993b), its low concentration and efficacy after intramuscular injection which 
limits its use in a dart, and its side-effects, which include cortical arousal, tachycardia, 
hypertension, hyperthermia and muscle rigidity (Bowdle 1988). Due to the limitation of the 
current therapies, novel pharmacological agents are needed to reverse and prevent opioid-
induced respiratory depression without causing unwanted side-effects, and preserving the 
therapeutic value of opioids, particularly when they are used as analgesic and immobilizing 
agents. 
 
Improved understanding of the mechanisms involved in the generation and control of respiration 
allows for the investigation of potential novel pharmacological agents to reverse opioid-induced 
respiratory depression. Investigations have focused predominantly on neurotransmitters and 
other agents that activate pathways that alter the production of adenosine 3’,5’-monophosphate 
(cAMP). The rationale for this approach is that cAMP-dependent protein kinase activities 
increase neuronal activity which is particularly important for the generation and maintenance of 
stable respiratory rhythm (Ballanyi et al. 1997). Additionally, opioid receptor activation causes a 
decrease in cAMP; opioid receptors are coupled to Gi/o proteins which inhibit adenylyl cyclase, 
an enzyme essential for the production of cAMP (Ballanyi et al. 1997; Manzke et al. 2003). 
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Initial approaches to stimulate respiration focused on increasing cAMP by reducing its 
breakdown. Methylxanthines, like theophylline, aminophylline and caffeine, which block 
phosphodiesterase, the enzyme that catabolises cAMP, have some respiratory stimulant effects 
(Eldridge et al. 1983; Wilken et al. 2000). These respiratory effects are not due solely to their 
effects on phosphodiesterase but also to their antagonistic effects on adenosine A1 and A2 
receptors (Rang et al. 2003). However, methylxanthines appear to be clinically useful only as 
bronchodialators and for the treatment of central, non-drug induced, apnoeas (Peña & García 
2006; Rang et al. 2003; Wilken et al. 1997).  
 
Recent steps at increasing respiratory neuronal cAMP have focussed on the activation of 
receptors that directly increase the activity of adenylyl cyclase. A promising advance has been 
the discovery that dopamine D1-receptor activation can reverse opioid-induced neuronal 
respiratory depression (Lalley 2004; 2005b) through the activation of adenylyl cyclase (Ballanyi 
et al. 1997), without reversing opioid-induced analgesia (Lalley 2005a). However, at present 
there are no therapeutic D1-receptor agonists that cross the blood brain barrier (Lalley 2005a). 
Therefore, reversing opioid-induced neuronal respiratory depression with D1-receptor agonists in 
clinical situations currently is not feasible.  
 
More promising steps have been made at increasing cAMP in respiratory neurones with 
serotonergic ligands that activate specific serotonin receptors in the neuronal network. In the 
brainstem medullary raphe neurones that produce serotonin project onto respiratory neurones 
(Richter et al. 2003). Although endogenous serotonin plays an important neuromodulatory role 
during normal breathing (Cao et al. 2006; Hodges & Richerson 2008; Richter et al. 2003), its 
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effects on respiratory neurones appear to be complex and are not clearly defined (Bonham 1995). 
Serotonin can have both a facilitatory and depressive effect on respiratory function (Sessle & 
Henry 1985), which can be attributed to its activation of multiple 5-HT-receptor subtypes found 
throughout the respiratory network (Peña & García 2006). The facilitatory effects of serotonin 
appear to be associated with an activation of serotonin 5-HT1A, 5-HT2A, 5-HT2B, 5-HT4 and 5-
HT7-receptors (Lalley et al. 1995; Manzke 2004; Peña & García 2006; Richter et al. 2003).  
 
5-HT4 receptors, particularly the splice variant 5-HT4(a), are highly expressed in respiratory 
neurones of the pre-Bötzinger complex (Manzke et al. 2003). Manzke et al. (2003) demonstrated 
that 5-HT4(a) and µ-opioid receptors were coexistent on these neurones and both were coupled to 
adenylyl cyclase in a antagonistic manner; µ-opioid receptors decrease cAMP through Gi 
proteins and 5-HT4(a) receptors increase cAMP through Gs proteins (Fig. 3). Similarly, 5-HT7 
receptors also are positively coupled to adenylyl cyclase (Vanhoenacker et al. 2000) and 
coexistent with opioid receptors on these neurones (Richter et al. 2003; Fig. 4). However, the 
expression of 5-HT7 receptors in the pre-Bötzinger complex is relatively low (Richter et al. 
2003). The coexistence of µ-opioid receptors and 5-HT4(a) and 5-HT7 receptors on pre-Bötzinger 
complex respiratory neurones, and the contrasting action of the opioids and serotonin on 
adenylyl cyclase, has allowed for the use of serotonergic ligands with 5-HT4(a) and 5-HT7 actions 
to reverse opioid-induced depression of respiratory neurones (Manzke et al. 2003; Richter et al. 
2003; Wang et al. 2007).  
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Figure 3. Signal transduction pathways of the 5-HT4(a) and µ-opioid receptors: abbreviations: 
adenylyl cyclase (AC), protein kinase (PKA), cyclic adenosine 5’, 3’-monophosphate (cAMP), 
serotonin 4(a) receptor (4(a)), µ-opioid receptor (µ), stimulating or inhibitory hetero-trimeric 
guanine-nucleotide-binding protein (Gs or Gi), hetero-trimeric guanine-nucleotide-binding 
protein α13 (Gα13), A-kinase-anchoring protein 110 (AKAP 110) (Redrawn from Figure 71, 
Manzke T. Unpublished PhD thesis, University of Göttingen, Göttingen, Sweden). 
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Figure 4. Signal transduction pathways of the 5-HT1A, 5-HT7 and µ-opioid receptors: 
abbreviations: adenylyl cyclase (AC), protein kinase (PKA), cyclic adenosine 5’, 3’-
monophosphate (cAMP), serotonin 7 receptor (7), serotonin 1A  receptor (1A), µ-opioid receptor 
(µ), stimulating or inhibitory hetero-trimeric guanine-nucleotide-binding protein (Gs or Gi) 
(Taken from Figure 72, Manzke T. Unpublished PhD thesis, University of Göttingen, Göttingen, 
Sweden). 
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The possibilities of reversing opioid-induced neuronal respiratory depression with 5-HT2A, 5-
HT2B and 5-HT1A receptor agonists also have been studied. Although 5-HT2A and 5-HT2B 
receptors are expressed in the pre-Bötzinger complex and their activation in the absence of 
opioids increases respiratory activity (Lalley et al. 1995; Manzke 2004; Peña & Ramirez 2002), 
agonists of these receptors are not able to reverse opioid-induced neuronal respiratory depression 
(Manzke 2004). These findings could be explained by these receptors being coupled to 
phospholipase C, which activates respiratory activity via mechanisms that are distinct to those 
which are activated via adenylyl cyclase (Manzke 2004; Fig. 5). 5-HT1A receptors, on the other 
hand, are coupled to adenylyl cyclase, but they inhibit adenylyl cyclase and decrease the 
production of cAMP (Richter et al. 2003; Fig. 4). However, agonists of 5-HT1A receptors 
stimulate respiration (Garner et al. 1989; Mendelson et al. 1990) and reverse opioid-induced 
neuronal respiratory depression (Manzke 2004; Sahibzada et al. 2000; Wang et al. 2007). How 5-
HT1A agonists affect respiratory function and reverse opioid-induced neuronal respiratory 
depression is not understood, but possible mechanisms have been proposed. In the central 
respiratory network, 5-HT1A receptors are the serotonin receptor subtype expressed most 
extensively and these receptors are involved in depressing respiratory neuronal excitability 
(Richter et al. 2003). Activation of post-synaptic 5-HT1A receptors in pontine areas of the 
brainstem inhibits apneusis, which is a marked prolongation of inspiration, by inhibiting the 
activity of neurones that cause prolonged inspiratory effort (Barnes & Sharp 1999; Lalley et al. 
1994a; Pierrefiche et al. 1998). This proposed mechanism couples with the proposed model by 
Manzke (2004) that suggests that 5-HT1A agonists shift opioid-induced breathing patterns from a 
three-phase to a two-phase cycle by inhibiting early-inspiratory and post-inspiratory neurones, 
thus increasing respiratory rate. Although these proposed mechanisms have not been linked to  
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Figure 5. Signal transduction pathways of the 5-HT2A, 5-HT2B and µ-opioid receptors: 
abbreviations: serotonin 2A receptor (2A), serotonin 2B receptor (2B), phospholipase C (PLC), 
inositol 1,4, 5-triphosphate (IP3), diacylglycerol (DAG), protein kinase C (PKC), hetero-trimeric 
guanine-nucleotide-binding protein q (Gq), adenylyl cyclase (AC), protein kinase (PKA), cyclic 
adenosine 5’, 3’-monophosphate (cAMP), µ-opioid receptor (µ), inhibitory hetero-trimeric 
guanine-nucleotide-binding protein (Gi) (Taken from Figure 74, Manzke T. Unpublished PhD 
thesis, University of Göttingen, Göttingen, Sweden) . 
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the reversal of opioid-induced neuronal respiratory depression they may be plausible because the 
action of opioids on pontine neurones can cause apneustic respiratory arrhythmias (Lalley 2005c; 
Pattinson 2008).  
 
Other mechanisms also may account for the ability of 5-HT1A agonists to reverse opioid-induced 
neuronal depression. 5-HT1A agonists are believed to reverse opioid-induced neuronal respiratory 
depression by increasing the excitability of respiratory motoneurones in the spinal cord (Teng et 
al. 2003). 5-HT1A agonists also decrease the inhibitory effects of serotonin on respiratory 
neurones in the pre-Bötzinger complex by activating pre-synaptic 5-HT1A autoreceptors in 
brainstem raphe neurones (Oertel et al. 2007). Activation of these autoreceptors leads to a 
decrease in opioid-induced neuronal serotonin release and dorsal raphe neuron activity, which 
results in antagonism of opioid-induced neuronal respiratory depression (Florez et al. 1972; 
Lalley et al. 1997; Tao & Auerbach 1995; Trulson & Arasteh 1986). It is possible that one, or a 
combination, of the above effects is involved in the reversal of opioid-induced respiratory 
neuronal depression by 5-HT1A agonists, but further clarification is needed. 
 
The effects of serotonergic ligands on the reversal of opioid-induced neuronal respiratory 
depression are not limited to the central nervous system but also involve haemodynamic effects 
that influence respiratory function. The most important of these haemodynamic effects is the 
reversal of opioid-induced pulmonary vasoconstriction (Haigh 1990; Heard et al. 1990; Heard et 
al. 1996; Santiago & Edelman 1985); pulmonary vasoconstriction decreases pulmonary 
perfusion and negatively alters ventilation perfusion ratios and alveolar gas exchange (Lumb 
2005). Other important haemodynamic effects would include the reversal of opioid-induced 
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systemic vasoconstriction and alterations in blood pressure (Hannon & Bossone 1991; Heard et 
al. 1990; Heard et al. 1996); both of these effects may decrease tissue perfusion and tissue 
oxygenation.  
 
Serotonin generally causes pulmonary vasoconstriction (Gyermek 1996), an effect that is 
attributed predominantly to its binding to 5-HT2A and 5-HT1B/1D receptors in the pulmonary 
vascular bed (Cortijo et al. 1997; Morcillo & Cortijo 1999). However, there also is evidence that 
serotonin can mediate vasodilatation directly through the activation of 5-HT4 and 5-HT7 
receptors located on vascular smooth muscle (Morcillo & Cortijo 1999); in sheep activation of 5-
HT4 receptors causes potent endothelium-independent relaxation of pulmonary veins (Cocks & 
Arnold 1992), and in rabbits activation of 5-HT7 receptors causes nitric oxide-independent 
vasodilatation in pulmonary vessels (Morecroft & MacLean 1998). 5-HT1A receptors have not 
been identified in pulmonary blood vessels, at least so far in humans (Cortijo et al. 1997), rats 
and pigs (Cortijo et al. 1997; Ullmer et al. 1995), and their agonists do not have any direct action 
on these vessels (Ogawa et al. 1995). However, 5-HT1A agonists cause systemic vasodilatation 
(Dabiré et al. 1990). This vasodilatation is believed to occur via central effects on vasomotor 
centres which result in a decrease in sympathetic tone (Blessing 2004; Dabiré et al. 1990; 
Ootsuka & Blessing 2003; Saxena & Villalón 1990; Zwieten 1996). This decrease in sympathetic 
tone is important as it may reverse the activation of sympathetic neurones brought about as a 
direct effect of the opioids (Roquebert & Delgoulet 1988) and from opioid-induced hypoxia and 
hypercapnia (Heard et al. 1990; Heard et al. 1996). This decrease in sympathetic tone results in a 
decrease in systemic and pulmonary vascular resistance, and may increase pulmonary perfusion 
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thereby improving ventilation perfusion ratios and gas exchange (Kadowitz & Hyman 1973; 
Nunn 1993).  
 
The decrease in sympathetic tone caused by 5-HT1A agonists not only decreases vascular 
resistance but it also affects the heart by causing bradycardia (Dabiré et al. 1990; Saxena & 
Villalón 1990). Other serotonergic ligands also affect the heart. 5-HT3 receptor agonists cause 
bradycardia by activating receptors on postganglionic cardiac sympathetic nerve fibres (Dabiré et 
al. 1990). 5-HT2 receptor agonists cause tachycardia and positive ionotropy by inducing the 
release of catecholamines from adrenomedullary chromaffin cells (Saxena & Villalón 1990). 5-
HT4 receptor agonists also cause tachycardia and positive ionotropy, which results in an increase 
in blood pressure, by activating receptors in the cardiac atria (Kaumann & Levy 2006; Villalón et 
al. 1991). These effects of the 5-HT4 receptor agonists appear to occur only in pigs and humans. 
In other species, including cats, dogs, rats and rabbits, tachycardia is not induced by the 
activation of 5-HT4 receptors but rather by the activation of 5-HT1 and 5-HT2 receptors (Langlois 
& Fischmeister 2003).  
 
Although the specific cardiovascular effects of serotonin and its ligands have been determined, 
little is known about how these effects alter cardiac output or tissue perfusion. In spite of the 
many studies on the respiratory neuronal effects of serotonin during opioid-induced respiratory 
depression, few, if any, have measured the crucial physiological variables of PaO2 and PaCO2. 
Additionally, very few of these studies have been done in unanaesthetised animals without the 
confounding effects of general anaesthetics. Furthermore, most of the studies done to date have 
been done in laboratory animals and nothing is known about the effects of serotonin and its 
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ligands in other species including wildlife. Therefore, nothing is known about how the 
cardiorespiratory effects of serotonin and its ligands influence blood and tissue oxygenation and 
carbon dioxide removal in animals that receive opioids for clinical applications. 
 
1.3 Consequences of capture-induced hyperthermia and opioid-induced respiratory 
depression 
In all animals there is a lower and upper critical body temperature, also known as the critical 
thermal minimum or maximum, beyond which cellular damage occurs (Leon 2007; Willmer et al. 
2005). In most placental mammals the upper critical limit is between 42˚C and 44˚C (Willmer et 
al. 2005). However, there is no set upper body temperature that will predict thermal injury in an 
individual and sometimes this injury occurs at temperatures below a proposed upper critical 
temperature for that species (Leon 2007). Heat, or heat cytotoxicity, causes cellular injury by 
causing disruption to metabolic pathways, disturbances in cellular energy supplies, and the 
degradation and aggregation of proteins which leads to the breakdown of enzymatic processes 
(Willmer et al. 2005; Yan et al. 2006). It also affects membrane structures so that various 
transport systems into and between cells are disrupted, thereby upsetting intracellular conditions 
and cellular metabolism (Willmer et al. 2005; Yan et al. 2006). To complicate matters further, 
heat causes an increased need for oxygen and energy substrates as it increases cellular 
metabolism (Willmer et al. 2005; Yan et al. 2006).  
 
The cytotoxic, metabolic and hypoxic effects of heat in the body may cause many cells to 
undergo lethal damage, which could lead to apoptosis or even cellular necrosis (Yan et al. 2006). 
The consequences of heat-induced cell damage has been studied extensively in humans (Leon 
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2007; Yan et al. 2006) and in animal models of heat stroke (Damanhouri & Tayeb 1992). Heat 
stroke in both man and other animals is associated with abnormally high body temperatures and 
diffuse tissue injury which can involve gastrointestinal failure, renal failure, hepatic failure, 
disseminated intravascular coagulation, myocardial failure, skeletal muscle cytolysis, 
encephalopathy, hypoxemia, metabolic acidosis, hyperkalaemia and cardiogenic shock 
(Bouchama et al. 2005; Haskins 1995; Leon 2007; Yan et al. 2006). One of the consistent 
findings in heat stroke is that the gastrointestinal barrier is damaged in the early stages 
(Bouchama et al. 2005; Bynum et al. 1977; Hall et al. 2001) causing a leakage of endotoxins and 
the subsequent release of inflammatory cytokines (Leon 2007; Yan et al. 2006), which, in 
conjunction with the release of other inflammatory mediators from damaged tissues, results in a 
systemic inflammatory response syndrome (Bouchama & Knochel 2002; Leon 2007; Yan et al. 
2006). This systemic inflammatory response syndrome, in combination with the effects of heat 
cytotoxicity, can result in multiple organ dysfunction and failure (Bouchama & Knochel 2002; 
Haskins 1995).  
 
Heat stroke in man and other mammals can be caused either by passive exposure to hot 
environmental conditions, which is known as classical heat stroke, or by strenuous physical 
exercise, which is know as exertional heat stroke (Bouchama & Knochel 2002; Jessen 2001; Yan 
et al. 2006). Although classical heat stroke can occur in wild animals, especially if they are 
compromised by dehydration or disease, it is unlikely to play a major role in capture-induced 
hyperthermia. On the other hand, exertional heat stroke, which often is associated with 
rhabdomyolysis, hyperkalaemia, hypocalcaemia, myoglobinaemia and myoglobinurea (Haskins 
1995), may play a role because these symptoms are often seen post-capture and are also 
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associated with capture myopathy (Harthoorn 1976). It is for this reason that it has been 
proposed that heat stroke and capture-induced hyperthermia are synonymous, and that they play 
a role in capture myopathy (Antognini et al. 1996; Cheney & Hattingh 1987; Ebedes et al. 1996; 
Gericke et al. 1978; Meltzer & Kock 2006b). However, this proposal is based on the assumption 
that capture-induced hyperthermia is caused by physical exercise, an assumption that is not 
always true as capture-induced hyperthermia occurs even when minimal physical exercise occurs 
(Bakken et al. 1999). Therefore, although capture-induced hyperthermia and heat stroke share 
some similarities, the mechanisms that cause the increase in body temperature in these two 
phenomena appear to be distinct. However, both may play a role in the cause of capture 
myopathy.  
 
Capture myopathy is a common cause of death or morbidity after capture operations (Ebedes et 
al. 1996; Harthoorn 1976; Meltzer & Kock 2006b).  Although it is primarily associated post-
mortally with visible pathology of cardiac and skeletal muscles, lesions are not always seen in 
muscle, and muscle damage is not always the primary cause of death (Ebedes et al. 1996; 
Harthoorn 1976; Kock et al. 2006). Harthoorn (1976) described differing degrees of capture 
myopathy which he attributed to differing levels of stress and exertion an animal is exposed to 
during capture. The most lethal of these is the hyper-acute form which is associated with per-
acute death within an hour of capture (Ebedes et al. 1996) and is attributed to heart failure caused 
by a profound acidaemia and hyperkalaemia (Harthoorn 1976). In the acute form animals die 
within 12 hours of capture and death is attributed to heart failure or pulmonary oedema 
(Harthoorn 1976). The sub-acute form is associated with damage to muscle and other major 
organs, like the lung, liver and kidneys, with death occurring from these complications within 
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one to two weeks after capture (Harthoorn 1976). In the chronic form death usually occurs only 
weeks to months after capture and usually arises when animals are re-captured; it is attributed to 
either the development of the acute form of the disease, or heart failure which results from 
chronic myocardial fibrosis (Ebedes et al. 1996; Harthoorn 1976).   
 
The primary causes of capture myopathy are believed to be overexertion during a chase and the 
stress associated with the capture (Ebedes et al. 1996; Gericke et al. 1978; Harthoorn 1976; 
Hofmeyr et al. 1973; Kock et al. 2006). The pathophysiology of capture myopathy is very similar 
to that of exertional rhabdomyolysis in man and horses (Aleman 2008; Criddle 2003; Valentine 
2008) and Porcine Stress Syndrome in pigs (Mitchell & Heffron 1982), as patients suffering 
from these syndromes all present with muscle stiffness, hyperthermia, metabolic acidosis, 
myoglobinuria, increased serum creatine kinase and potassium concentrations. These changes are 
believed to be brought about by a combination of a stress-induced increase in serum 
catecholamines (Ebedes et al. 1996; Gericke et al. 1978; Harthoorn 1976), an increase in 
anaerobic metabolism due to excessive exertion (Ebedes et al. 1996; Harthoorn 1976), and a 
derangement in metabolism (Mitchell & Heffron 1982). Anaerobic metabolism in muscle cells 
results in an increase in lactic acid production and a disturbance of the active transport of 
electrolytes in and out of cells. These effects result in cellular damage and the leakage of 
myoglobin, cellular enzymes like creatine kinase, and other constituents like potassium, 
phosphate, lactic acid and other inorganic acids into the blood stream (Criddle 2003; Guyton & 
Hall 1997; Harthoorn 1976; Meltzer & Kock 2006b). The resultant metabolic acidosis further 
compounds the hyperkalaemia as hydrogen ions displace potassium ions from cells (Guyton & 
Hall 1997). This hyperkalaemia, in combination with severe acidaemia, is believed to be the 
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cause of heart failure in the hyper-acute and acute forms of capture myopathy (Gericke et al. 
1978; Harthoorn 1976). Pulmonary oedema, which also is seen in the acute form, is possibly 
caused by pulmonary hypertension resulting from acidaemia and an increase in sympathetic and 
adrenal discharge (Harthoorn & Young 1976), but also may occur as a result of heart failure 
(Harthoorn 1976). Renal failure, which occurs in the acute form, can occur if muscle damage is 
severe and is brought about by the combination of renal vasoconstriction and the nephrotoxic 
effects of myoglobinaemia (Criddle 2003; Harthoorn 1976). The damage seen in other organs of 
animals with capture myopathy appears to occur mainly because of hypoperfusion, which results 
in anaerobic metabolism and the build up of toxic metabolites (Harthoorn 1976).    
 
It is apparent that anything that would increase anaerobic metabolism during capture would 
enhance the severity of capture myopathy. When an animal over-exerts itself its ability to 
metabolise aerobically is limited by the body’s cardiovascular and respiratory capacity to deliver 
oxygen to cells (Guyton & Hall 1997). During capture this capacity may be diminished by 
generalized vasoconstriction caused by excessive discharge of the sympathetic nervous system 
following stress (Kock et al. 2006). Importantly, this vasoconstriction may directly affect oxygen 
and nutrient supply to muscles as the sympathetic nervous system plays a major role in 
regulating muscle blood flow during exercise (Rowell 1997; 2004; Thomas & Segal 2004). 
Hyperthermia also will increase anaerobic metabolism as it increases cellular metabolism; for 
every 1˚C increase in body temperature metabolism increases by 10-12% (Criddle 2003; Guyton 
& Hall 1997). At body temperatures above 41-42˚C in mammals the oxygen requirement of cells 
exceeds the cardiovascular capability for sufficient oxygen delivery leading to hypoxia and 
cellular damage (Grint et al. 2007; Haskins 1995). Anaerobic metabolism also will be increased 
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by the insufficient supply of oxygen to the lungs, a scenario that may occur during chemical 
capture, where opioid drugs may cause respiratory depression, and recumbency may hinder lung 
expansion and ventilation (Kock et al. 2006). 
 
Opioid-induced respiratory depression is important not only in capture myopathy, but for other 
reasons it also may influence the survival of an animal during and after chemical immobilization. 
As discussed in section 1.2.2, opioids cause hypoventilation, ventilation perfusion mismatching, 
shunting of blood in the lungs, and a decrease in oxygen diffusion across the alveolar membrane. 
The consequence of these effects is hypoxia and hypercapnia (Nunn 1993). Hypoxia means that 
less energy is available to the cell, and metabolites like hydrogen and lactate ions build up 
(Guyton & Hall 1997; Nunn 1993). These ions may escape into the circulation where they can 
cause a metabolic acidosis, but, in the brain, the blood-brain barrier is relatively impermeable to 
charged ions, so that these ions build up in neurones and cause an intracellular acidosis (Lumb 
2005). The consequences of cellular energy depletion and acidosis are the development of gross 
abnormalities in ion channel function, which leads to abnormal intracellular and extracellular 
ionic gradients, leading to cell death (Lumb 2005). Although the organ believed to be the most 
susceptible to hypoxic damage is the brain, and death due to neuronal depression and damage 
usually occurs (Lumb 2005), under special circumstances other organs may be more susceptible 
(Wilson & Benuhof 2005). During anaesthesia, the heart is the organ that is most susceptible to 
hypoxic damage because hypoxaemia generally promotes cardiac irritability and arrhythmias as 
the increase in oxygen demand, caused by sympathetic and catecholamine myocardial 
stimulation, and the decrease in oxygen supply, tips the normal balance between myocardial 
oxygen supply and demand (Wilson & Benuhof 2005). In addition, if hypoxaemia is severe, with 
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arterial oxygen haemoglobin saturations below 60%, the cardiovascular system is severely 
affected and blood pressure falls rapidly due to vasodilatation. Shock eventually develops, and 
the heart either fibrillates or arrests (Wilson & Benuhof 2005).  
Hypercapnia also causes direct depression of both the myocardium and vascular smooth muscle, 
but at the same time it causes a reflex stimulation of the sympathoadrenal system which usually 
compensates for any cardiovascular depression (Lumb 2005). However, the reflex 
sympathoadrenal stimulation further exacerbates myocardial oxygen demand and may cause 
arrhythmias (Lumb 2005; Wilson & Benuhof 2005). Hypercapnia may further exacerbate 
hypoxia by diluting oxygen concentrations in the alveoli and shifting the oxygen haemoglobin 
dissociation curve to the right (Lumb 2005; Wilson & Benuhof 2005). It also can cause 
generalised pulmonary vasoconstriction which may alter the diffusion of oxygen across the 
alveoli membrane (Lumb 2005). Finally, if severe, with the arterial partial pressure of carbon 
dioxide (PaCO2) above 100mmHg, hypercapnia will cause profound neuronal depression which 
may result in narcosis and death (Guyton & Hall 1997; Lumb 2005; Wilson & Benuhof 2005).  
 
In summary, there is a distinct interplay between the side-effects of capture-induced 
hyperthermia and opioid-induced respiratory depression. The precise role each of these has to 
play in the development of capture-related morbidity and mortality has not been defined. 
Furthermore, little is known about the effects of capture-induced hyperthermia and the role it 
plays in capture myopathy, and whether its effects are associated with other adverse events like 
depression and anorexia in boma kept animals. In addition, it is also not known what affects 
opioid-induced respiratory depression has on wild animals post capture. However, before these 
questions are answered we need to establish the cause of capture-induced hyperthermia, and 
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determine how opioid drugs affect respiratory function and pulmonary performance. We also 
need to determine whether opioid-induced respiratory depression can be reversed adequately 
without altering the immobilizing and sedative effects of the drugs used to chemically 
immobilize wildlife. 
 
1.4  Thesis aims 
My interest is in pathophysiological events associated with the capture process that may lead to 
immediate or delayed morbidity and mortality in wildlife. I have chosen to focus on two of these 
events, capture-induced hyperthermia and opioid-induced respiratory depression, because they 
are adverse events that consistently occur during capture procedures, and because both can cause 
morbidity and mortality.  
 
Chapter 1. Sections 1.1 and 1.3 outline our current understanding of the possible causes and 
effects of capture-induced hyperthermia. Although hyperthermia is a common occurrence during 
capture, very little is known about its cause. Consequently, interventions to either prevent or treat 
capture-induced hyperthermia have been instituted based on speculation that capture-induced 
hyperthermia is related to either the ambient temperature, the activity levels of the animal, the 
drug’s effects, or the effects of stress, during capture. Therefore, I aimed to investigate the 
mechanisms and patterns of capture-induced hyperthermia.  
 
Section 1.2 and 1.3 outline our current understanding of the possible causes and effects of 
opioid-induced respiratory depression and also summarise the current understanding of the role 
serotonin plays in the regulation of respiration and how its actions can be used to reverse opioid-
  
48 
induced respiratory depression. Reversal of opioid-induced respiratory depression, without 
reversal of the opioids desired effects, is of paramount importance to both veterinary and human 
medicine and anaesthesia. However, few agents are available clinically which meet this criteria, 
and therefore there is a need for new agents. To date, the focus of the research on reversing 
opioid-induced respiratory depression has been placed on reversing neuronal depression in the 
respiratory network. The majority of the studies conducted in this field have assessed only the 
effects of specific receptor ligands on respiratory neuronal activity or on respiratory rate, rhythm 
and pattern. Currently no study has examined how the serotonergic ligands effects on 
cardiorespiratory function influence blood gases and whether these ligands can be used to 
reverse opioid-induced respiratory depression, without reversing chemical immobilization. I 
aimed therefore to investigate systematically if serotonergic ligands can be used to reverse 
opioid-induced respiratory depression, by improving blood gases, in chemically immobilized 
animals. I also aimed to determine how the opioid etorphine, that is used to chemically 
immobilize wildlife, affects cardiorespiratory function and pulmonary performance.   
 
Chapter 2. Although the continuous measurement of body temperature in springbok (Fuller et al. 
2005) and black wildebeest (Jessen et al. 1994) have provided some insights into body 
temperature changes during capture, little is known about the pattern and mechanisms of capture-
induced hyperthermia. I therefore measured body temperature in impala, at 10-minute intervals, 
with intra-abdominally implanted temperature-sensitive data loggers, throughout various capture 
procedures. To determine the role of capture drugs in capture-induced hyperthermia, I captured 
impala with and without immobilizing drugs. I assessed the effect of ambient temperatures and 
activity levels on capture-induced hyperthermia by measuring both throughout the capture 
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procedures. To assess the role of stress, I measured serum cortisol levels during capture, and 
compared body temperature and stress responses of animals in different groups that had been 
habituated to various periods of boma housing and handling. 
 
Chapter 3. Many capture drugs are believed to alter thermoregulation (Meltzer & Kock 2006a). I 
therefore investigated whether different capture drug combinations influence the magnitude of 
the capture-induced hyperthermia in impala. I also assessed whether the immobilizing effects of 
the different drug combinations, which influence the time from darting to when the animals 
became recumbent, influenced the magnitude of the capture-induced hyperthermia. Serum 
cortisol was used to determine whether the magnitude of the capture-induced hyperthermia could 
be correlated to the stress response induced by the use of the different capture drug combinations. 
In addition, heart rate, respiratory rate and peripheral haemoglobin oxygen saturation were 
measured to determine how the different drug combinations affected the cardiorespiratory 
system and how they were related to the magnitude of the capture-induced hyperthermia. 
 
Chapter 4. Respiratory depression is one of the major side-effects that is caused by the opioid 
drugs that are used to chemically capture wild animals (Kock et al. 2006; McKenzie 1993). 
Promising advances at reversing opioid-induced respiratory depression, without affecting the 
intended use of opioids, have been made using serotonergic ligands (Manzke 2004; Manzke et al. 
2003; Sahibzada et al. 2000). Unfortunately, though, very little is known about the effects of 
these drugs on cardiorespiratory function, and nothing is known about their effects in ungulates. I 
therefore investigated the cardiorespiratory effects of two experimental serotonergic ligands, 
which have differing mechanisms of action, in goats. I chose goats as my subjects as they have 
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been used before as a successful model for the affects of opioid immobilization on 
cardiorespiratory function in wild ungulates (Buss & Meltzer 2001; Heard et al. 1990; Heard et 
al. 1996), and they are easy to handle, therefore pre-immobilization data could be collected from 
them and they could be restrained with ease if the ligands reversed opioid immobilization. I 
measured blood gases, respiratory rates, heart rates and blood pressures to determine 
cardiorespiratory function, and times from injection to recumbency and the quality of 
immobilization, to determine the effects of these serotonergic ligands on chemical 
immobilization.        
 
Chapter 5. If serotonergic ligands are to be used to reverse opioid-induced respiratory depression 
during game capture, their effects need to be demonstrated during an actual capture procedure, 
and the drugs used need to be available commercially. At present, no commercially-available 
serotonergic drugs are able to reverse opioid-induced respiratory depression in humans (Lötsch 
et al. 2005; Oertel et al. 2007). I therefore investigated whether three commercially available 
serotonergic drugs, which have differing mechanisms of action, could be used to reverse opioid-
induced respiratory depression in chemically-immobilized impala. To evaluate respiratory 
function more extensively than previously (chapter four) I measured blood gases, respiratory 
rates, minute ventilation, tidal volumes, oxygen consumption and carbon dioxide production. To 
determine the effects of the serotonergic drugs on chemical immobilization I evaluated the 
quality of the immobilization by measuring the movements of the animals.     
 
Conclusion. In the conclusion I aim to give an overview of the findings that I have made and 
place these findings in context with existing knowledge. I will also discuss the significance of 
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these findings and make recommendations as to how they may be used to improve wildlife 
capture. I will also discuss the future and highlight the relevance of the findings of this thesis.        
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ABSTRACT: Respiratory depression is a common side-effect when opioids are used to immobilize 
wildlife. Serotonergic ligands have the potential to reverse opioid-induced respiratory depression. 
We therefore examined whether any of three serotonergic ligands could reverse this depression 
in etorphine-immobilized (0.07mg/kg) impala (Aepyceros melampus). The study took place from 
September to December 2007. Impala received intravenous injections of metoclopramide 
(10mg/kg, n=6), buspirone (0.05mg/kg, n=8), pimozide (1mg/kg, n=8), doxapram (1mg/kg, n=6), 
and control solutions, on separate occasions. During the immobilization, partial pressures of 
oxygen (PaO2 mmHg) and carbon dioxide (PaCO2 mmHg), respiratory rate (breaths/min), 
ventilation (l/min), peripheral O2 saturation (%), tidal volume (l) and the respiratory exchange 
ratio (RER) were measured before and after the injection of the experimental drugs. Etorphine 
immobilization caused respiratory depression and hypoxia (mean±SD, PaCO2=51±2 mmHg, 
PaO2=40±3 mmHg). Metoclopramide and buspirone, but not pimozide, attenuated the hypoxic 
effects of etorphine; at 3 min after injection, metoclopramide increased the PaO2 by 7.5±6.3 
mmHg and buspirone by 6±6.6 mmHg (F=3.9; P=0.02). These effects were similar to those of 
doxapram (8±7 mmHg, F=3.9; P>0.05). Neither metoclopramide nor buspirone significantly 
increased ventilation but they increased PaO2 by significantly improving the alveolar-arterial 
oxygen partial pressure gradient (A-a gradient, F=1.4; P<0.05), indicating an improvement in 
oxygen diffusion. Metoclopramide and buspirone transiently improved the blood oxygenation of 
opioid-immobilized impala, probably by improving ventilation-perfusion ratios, without 
reversing catatonic immobilization.  
Key words: Buspirone, doxapram, hypoxia, metoclopramide, opioid, pimozide, 
respiratory depression. 
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INTRODUCTION 
Potent opioid drugs are commonly used to chemically immobilize wild animals (Swan, 
1993; Meltzer and Kock, 2006). However, their use for this purpose comes at a cost to breathing 
and tissue oxygenation. Opioid receptor antagonists can counteract the depressant effects of 
opioids on respiration, but they block analgesia, and reverse anaesthesia, sedation and chemical 
immobilization (Bowdle, 1988; Swan, 1993). Other drugs that have been used to clinically 
reverse opioid-induced respiratory depression, like bemegride, nikethamide and picrotoxin, have 
lost favour because of their convulsogenic effects, or because they cause unwanted central 
nervous system arousal (Bowdle, 1988; Swan, 1993). Thus novel pharmacological approaches 
are needed to reverse opioid-induced respiratory depression while preserving the therapeutic 
value of opioids, particularly as analgesic and immobilizing agents. 
One such novel approach is the use of serotonergic ligands. The potential of serotonergic ligands 
to reverse opioid-induced respiratory depression, without reversing the analgesic or 
immobilizing effects of the opioids, has been demonstrated in several studies (Sahibzada et al., 
2000; Manzke et al., 2003; Richter et al., 2003; Meyer et al., 2006; Wang et al., 2007; Guenther 
et al., 2009) In opioid-immobilized goats that received serotonergic agonists, oxygen partial 
pressures improved without a change in ventilation (Meyer et al., 2006); this improvement was 
assumed to occur by the direct action of the agonists on pulmonary vessel diameter, which would 
improve lung perfusion. We therefore investigated whether serotonergic agonists, currently 
commercially available, reverse opioid-induced respiratory depression in animals, as indicated 
by arterial blood oxygenation, without deleterious effects on the target action of the opioids. 
From the repertoire of serotonergic drugs already available for human and animal use, 
experimental drugs were selected for their effects on 5-HT4, 5-HT1A and 5-HT7 serotonin 
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receptors, and consequently, their role in the maintenance of respiratory rhythm (Richter et al., 
2003). Of these drugs metoclopramide was selected for its 5-HT4 receptor agonist effects 
(Langlois and Fischmeister, 2003; Rang et al., 2003), buspirone for its 5-HT1A receptor agonist 
effects (Rang et al., 2003) and pimozide for its 5-HT7 receptor agonist effects (Roth et al., 1994). 
The effects of these experimental drugs were compared to those of doxapram, an analeptic still 
used commonly to reverse opioid-induced respiratory depression (Bowdle, 1988), particularly 
during chemical immobilization (Swan, 1993). Impala (Aepyceros melampus) were chosen as the 
experimental animals, because they are known to be particularly susceptible to the respiratory 
depressant effects of opioids during chemical immobilization (Burroughs et al., 2006) and 
because they are captured frequently for African wildlife management.  The hypothesis was that 
all three of the selected serotonergic drugs would attenuate opioid-induced respiratory depression 
and hypoxia in chemically immobilized impala.  
 
MATERIALS AND METHODS 
The procedures were approved by the University of the Witwatersrand’s Animal Ethics 
Screening Committee (clearance number 2005/80/05). The study took place from September to 
December 2007 at the Lichtenburg Game Breeding Centre (26º07'S, 26º07'E) of the South 
African National Zoological Gardens, 220 km west of Johannesburg, South Africa.  
 
Animals  
Nineteen healthy adult male (n=2) and female (n=17) impala (Aepyceros melampus), 
weighing 36±6 kg (mean±SD), were used. The impala were caught from the wild and transported 
to bomas (holding pens with solid wooden pole walls) where they were housed for three months 
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before the experimental trials. Throughout the trials, the impala were housed in 10 m x 5 m 
bomas, with a maximum of five impala per boma. The impala received lucerne/alfalfa 
(Medicago sativa) and water ad libitum and the bomas were cleaned regularly, so the impala 
were accustomed to occasional human presence. 
 
Drugs 
For each trial, we injected etorphine intramuscularly (I.M.), using a dart (see Table 1 for 
details of the drugs used). On separate days, the experimental drugs and their controls were 
injected as intravenous (I.V. into the jugular vein following placement confirmation by 
withdrawing an adequate volume of blood into the syringe) boluses into immobilized animals. 
Doxapram was injected at a mid-range dose recommended by the manufacturers. The doses of 
metoclopramide, buspirone, and pimozide were established in a pilot dose-response study, in a 
separate group of impala (n=15), as mid-range doses which improved respiratory rate or arterial 
blood oxygenation. As controls, the vehicles, injectable water and DMSO, were injected on their 
own, at the volumes used to dissolve the experimental drugs. The animals received only two of 
the experimental drugs and one or both of the controls, on separate occasions. Animals were 
darted a maximum of four times only and, if they were not fully immobilized or clinically unfit 
on one of these occasions, experimental procedures were not performed. The drugs and their 
controls were used randomly across the group of animals; ten animals received water, eight 
buspirone, six metoclopramide, six doxapram, eight pimozide and five DMSO. 
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TABLE 1. Agents used during the experimental trials 
 
Agent  Manufacturer  Dose  Concentration  Vehicle  Known receptor activity  References 
    mg/kg  mg/ml    Primary Secondary   
              
Etorphine 
hydrochloride 
 Novartis, 
Johannesburg, 
South Africa 
 
0.071 
 
9.8 
 
water 
 
µ-opioid 
agonist 
κ & σ-opioid 
agonist 
 (Roquebert and 
Delgoulet, 1988) 
              
Doxapram 
hydrochloride 
 Intramed, Port 
Elizabeth, 
South Africa 
 
1 
 
20 
 
water 
 
peripheral 
chemoreceptors 
central 
effects 
(mechanism  
not known) 
 (Nishino et al., 
1982; Martindale, 
1999) 
              
Metoclopramide 
Hydrochloride 
 
Sigma-Aldrich, 
Aston Manor, 
South Africa 
 
10 
 
500 
 
water 
 
5-HT4 agonist 
D2 antagonist 
5-HT3 
antagonist 
 (Martindale, 
1999; Langlois 
and Fischmeister, 
2003; Rang et al., 
2003) 
              
Buspirone 
hydrochloride 
 
Sigma-Aldrich 
 
0.05 
 
5 
 
water 
 
5-HT1A agonist 
dopamine 
receptor 
dependant 
effects 
 (Riblet et al., 
1982; Taylor, 
1988; Martindale, 
1999; Rang et al., 
2003) 
              
Pimozide  Sigma-Aldrich  1  15  DMSO  5-HT7 agonist D2 antagonist 
 
 (Roth et al., 1994; 
Rang et al., 2003) 
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Experimental procedure 
Each impala was immobilized with etorphine hydrochloride on three or four 
occasions, separated by at least 72 hours, by darting them with a dart gun (Sabi 500, 
SABI Werkswinkel t/a Magnum Arms, Nelspruit, South Africa; Pneu-Dart dart type 
P, 3 ml volume, 25 mm long, wire-barbed needle, Pneu-Dart, Williamsport, USA). 
With the use of a powder charge the darts were fired over a 4-5 m distance into the 
gluteus muscles. Once an impala was fully immobilized and became recumbent, it 
was moved to a shaded boma, where it was placed on a veterinary scale (Associated 
Scale Corporation, Johannesburg, South Africa) and held in a sternal recumbency. 
The impala was blindfolded and cotton wool was placed in its ears, to reduce external 
sensory stimuli.  
The impala’s ear was shaved and swabbed with 5 % chlorhexidine gluconate 
(Hibitane, Astra Zeneca, Johannesburg, South Africa) in 100 % ethanol, and a 22 
gauge intravenous catheter (Introcan, B/Braun, Melsungen, Germany) was placed in 
one of the auricular arteries. To ensure continuous measures of peripheral 
haemoglobin oxygen saturation, two veterinary pulse oximeters (Nonin 9847V, Nonin 
Medical, North Plymouth, USA) were clipped (lingual sensor 2000SL) to the wall of 
the vulva in female impala, or to a tented skin fold in the perineum of male impala, 
and on the skin (2000T animal transflectance sensor) at the tail base (secured with 
adhesive tape). Rectal temperatures were measured with a thermocouple thermometer 
(BAT-12, Physitemp, Clifton, USA) and were used as the body temperature needed to 
calculate water vapour pressure in alveolar air and to correct for blood gas 
measurements. A clear canine anaesthetic face mask (J-298C, Jorgensen Laboratories, 
Loveland, USA) was placed over the muzzle of the impala, positioned so as to limit 
the dead space, and a gasket made from a latex glove formed a tight seal between the 
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impala’s muzzle and the face mask. The face mask was connected to a two-way valve 
which directed all the expired air into a PowerLab Exercise Physiology System 
(ML870B80, ADIntruments, Castle Hill, Australia). This system consisted of a 
respiratory flow head (MLT1000L) linked to a spirometer (ML140) and a gas mixing 
chamber (MLA245) from which the expired gas temperature was measured and 
mixed gas was sampled through a gas analyser (ML205). The data from these 
components was collected via the PowerLab 8/30 amplifier (ML870) and integrated 
with the Metabolic Module software. The simultaneous measurement of respiratory 
gas concentrations and air flow allowed for the calculation of (at BTPS - body 
temperature and pressure saturated) minute ventilation (l/min), oxygen consumption 
(VO2, l/min), and carbon dioxide production (VCO2, l/min) and the respiratory 
exchange ratio (RER = VCO2/VO2). Respiratory rate and tidal volume also were 
measured. Each day the spirometer was calibrated using a 3l calibration syringe and 
the gas analyzer with a calibration gas (12% O2, 5.1% CO2 Air Products, 
Johannesburg, South Africa) and inspired air (20.93% O2, 0.03% CO2).    
Once impala were instrumented, which took ~ 8 min (490±116 s, mean±SD) 
from the time the impala became recumbent after darting, data recordings started. 
Data were recorded for 4 min before injection (injection time = 0 min) of the 
experimental drugs or controls, and for 18 min after injection. A 0.5 ml auricular 
arterial blood sample was drawn 2 min before, and at 3, 10, and 18 min after the 
injection (these time intervals were selected a priori); the catheter was flushed with 5 
iu/ml heparinized (Heparin, Intramed, Johannesburg, South Africa) saline. Directly 
after each sample was drawn, we measured the arterial partial pressure of oxygen 
(PaO2) and carbon dioxide (PaCO2) using a pre-calibrated blood gas analyzer with 
pre-calibrated blood gas cassettes (Roche OPTI CCA Analyzer + OPTI cassette B, 
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Kat Medical, Johannesburg, South Africa). Arterial samples were corrected for body 
temperature.  
During the data recording period, the impala’s movements were recorded and 
assigned a score (see Table 2). At the end of the recording period, all instruments 
were removed and the impala were returned to their bomas, where the action of 
etorphine was reversed by injection of 0.096 mg/kg diprenorphine hydrochloride I.V. 
(M5050, Novartis, Johannesburg, South Africa). A digital stop-watch was used to 
record the time that it took for the impala to stand after reversal.  
 
TABLE 2. Description used to score the movements of the impala during the 
immobilization 
 
Movement score Description 
0 no movement 
1 movement of the ear or tail 
2 movement of the ear and tail 
3 movement of the leg or head (with or without the ear or tail) 
4 movement of the leg and head (with or without the ear or tail) 
5 whole body movement with no attempt to stand  
6 whole body movement with an attempt to stand 
 
 
Ambient dry-bulb temperature and relative humidity were recorded by a data 
logger (Hobo H08-007-02, Onset Computer Corporation, Pocasset, MA, USA) which 
was placed in the boma where the experiment took place; ambient temperature ranged 
between 18 ˚C and 34 ˚C and water vapour pressure between 4.5 and 40.5 mmHg. 
Barometric pressure, which ranged from 642 mmHg to 650 mmHg, was measured by 
the on-board barometer of the blood gas analyzer, which we had calibrated against a 
Fortin mercury barometer (On, F.D & Co Ltd, United Kingdom).  
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Data analysis 
We used GraphPad Prism version 4.00 for Windows (GraphPad Software, San Diego, 
USA) for statistical analyses. The alveolar-arterial oxygen partial pressure gradient 
(A-a gradient) was calculated for an open system (constant pressure) from the formula: 
FiO2 (Pb – PH2O) – PaCO2 – PaO2 (Dill and Penrod, 1948), where FiO2 is the 
fractional inspired oxygen (0.209), Pb the measured barometric pressure (mmHg) and 
PH2O the water vapour pressure of saturated air in the alveoli. PH2O (mmHg) was 
calculated as 4.58 e{(17.27Tb)/(237.3 + Tb)}(Barenbrug, 1974), where Tb is the body 
temperature. We assumed that the partial pressure of CO2 in the alveoli was equal to 
the arterial partial pressure of CO2 (Riley et al., 1946; D' Alonzo and Dantzker, 1983; 
Lumb, 2005).  
The change in PaO2, PaCO2 and A-a gradient were calculated by subtracting 
post-injection values from the values measured at 2 min before the injection of the 
agents and controls, while changes in respiratory rate, minute ventilation, tidal volume, 
peripheral haemoglobin oxygen saturation (mean from the two measurement sites) 
and median movements were calculated by subtracting post-injection values from the 
average value measured 4 min pre-injection. Areas under the curves, depicting a 
change in response over time, were calculated for between 1-3, 4-10 and 11-18 min 
post-injection (these time intervals were selected a priori), for minute ventilation, 
respiratory rate, tidal volume, peripheral haemoglobin oxygen saturation, respiratory 
exchange ratio (RER) and median movements. For parametric data a one-way 
analysis of variance (ANOVA) followed by a Student Neuman Keuls (SNK) post-hoc 
test was used to test for differences in the changes in blood gas variables, A-a 
gradients, time to recumbency, time to standing, and also for differences in areas 
under the curves, between responses to injectable water, doxapram, metoclopramide 
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and buspirone and for differences between responses to injectable water, DMSO and 
pimozide. For non-parametric data a Kruskal-Wallis test with post-hoc Dunn’s 
multiple comparison test was used to test for these differences in the areas under the 
curves for median movements. To determine if metoclopramide or buspirone effects 
were different to those of the known respiratory stimulant doxapram within the first 3 
min after injection, a Student’s unpaired t-test was used for all the parametric 
variables, except for changes in movement (non-parametric data), where a Mann-
Whitney test was used. All results are reported as mean±SD, and a P<0.05 was 
considered statistically significant. 
 
RESULTS 
Effects of etorphine 
Etorphine (0.071±0.005 mg/kg) induced immobilization 223±86 s after 
darting. The time from darting to immobilization (time to recumbency) did not differ 
between the trial days (F=0.54, P=0.66), hence we assumed there to be no 
accumulative effects of using etorphine repetitively at a 72 h interval. The impala 
remained sedated and recumbent for the duration (22 min) of each trial. At the start of 
our recording period, 8-10 min after the impala became recumbent, peripheral 
haemoglobin oxygen saturation was 76±3 %, PaO2 40±3 mmHg, PaCO2 51±2 mmHg, 
A-a gradient 34±1 mmHg, minute ventilation 10.9±0.8 l/min, respiration rate was 
13±1 breaths.min-1, tidal volume 0.8±0.1 l, and the impala were in a state of anaerobic 
metabolism with RER = 1.04±0.04; these values did not differ across the trials 
(P>0.22). The rectal temperatures at the start of recording were 39.8±3 C and at the 
end 39.4±3 C, and the profile of the change in temperature was the same for all the 
trials.  
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After injection of water, peripheral haemoglobin oxygen saturation increased 
gradually by 6±7 % (Fig. 3A), PaO2 by 5.3±5 mmHg (Fig. 1A) and RER by 
0.09±0.01 over 18 min. These changes in peripheral haemoglobin oxygen saturation 
and PaO2 appeared not to be associated with the effects of an increase in respiratory 
rate, minute ventilation or tidal volume (Fig. 2), but rather to an improvement in the 
A-a gradients with time (Fig. 1C).  
 
Effects of doxapram 
When doxapram was injected, after etorphine immobilization, PaO2 increased 
by 8±7 mmHg (Fig. 1A) and peripheral haemoglobin oxygen saturation increased by 
9±9 % (Fig. 3A) by 3 min and remained at similar levels at 10 and 18 min after 
injection. Compared to water, the increases in PaO2 and peripheral haemoglobin 
oxygen saturation were significant only in the first 3 min after the injection of 
doxapram (PaO2 F=3.9, P<0.05, peripheral haemoglobin oxygen saturation F=4.2, 
P<0.05). Increases of PaO2 and peripheral haemoglobin oxygen saturation were 
accompanied by both an improvement in the A-a gradient (Fig. 1C) and an acute 
increase in minute ventilation (Fig. 2B); in the first 3 min after injection, both the A-a 
gradient (F=4.2, P<0.05) and minute ventilation (F=3.1, P<0.05) were increased 
compared to water. Although the increase in minute ventilation was significant, 
doxapram did not decrease the PaCO2 (F=2.1, P>0.05) within the first 3 min or 
thereafter.  
 
Effects of metoclopramide and buspirone 
Compared to water, injections of metoclopramide and buspirone both were 
followed by increased PaO2 at 3 min after injection (F=3.9, P<0.05; Fig. 1A); 
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metoclopramide increased the PaO2 by 7.5±6.3 mmHg and buspirone by 6±6.6 
mmHg. Although PaO2 increased further at 18 min (metoclopramide 11±6.2 mmHg, 
buspirone 9.3±9 mmHg), the change in PaO2 was not different from water at 10 and 
18 min (P>0.31). Metoclopramide increased the respiratory rate in the first 3 min after 
injection (F=3.0, P<0.05; Fig. 2A,). Following metoclopramide and buspirone 
injection, the increase in PaO2 was accompanied by improvement in the impala’s A-a 
gradients at 3 min (metoclopramide -5±4 mmHg, and buspirone -3±5 mmHg, F=1.4, 
P<0.05; Fig. 1C). 
Effects of pimozide and DMSO 
Compared to water, pimozide did not change the PaO2 (Fig. 4A), PaCO2, 
minute ventilation (Fig. 4C), the peripheral haemoglobin oxygen saturation or the A-a 
gradient, but did increase the respiratory rate in the first 3 min after injection (F=6.8, 
P<0.05; Fig. 4B,). However, there was no difference between pimozide + DMSO, and 
DMSO on its own ( F=6.8, P>0.05; Fig. 4B). Compared to water, DMSO increased 
the respiratory rate in the first 3 min after its injection (F=6.8, P<0.01; Fig. 4B).  
 
Comparison of the effects of metoclopramide or buspirone versus doxapram  
Metoclopramide’s effects on the respiratory variables in the first 3 min after 
injection were not different to those of doxapram (PaO2 change P=0.84, PaCO2 
change P=0.30, A-a gradient change P=0.57, peripheral haemoglobin oxygen 
saturation change P=0.25, respiration rate change P=0.32, minute ventilation change 
P=0.50, change in RER P=0.28), except for tidal volume which was smaller after 
metoclopramide injection than after doxapram injection (P=0.01). Similarly, in direct 
comparison to doxapram, buspirone’s effects on the respiratory variables in the first 3 
min after injection were not different from those of doxapram (PaO2 change P=0.56, 
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PaCO2 change P=0.48, A-a gradient change P=0.94, peripheral haemoglobin oxygen 
saturation change P=0.07, respiratory rate change P=0.65, minute ventilation change 
P=0.21). In this case there was no difference in the change in tidal volume (P=0.77), 
but the change in RER was lower (P=0.03) with buspirone than with doxapram.  
 
Effects on immobilization  
Metoclopramide caused an increase in movement of impala 4−10 min after its 
injection (P<0.05; Fig. 3B,). There were no other differences between the movement 
caused by doxapram, metoclopramide, buspirone and pimozide during any time 
period.  
 
Effects post-immobilization  
Diprenorphine completely reversed the immobilizing effects of etorphine and 
the impala were standing within 28-59s after its injection. Doxapram, metoclopramide 
and buspirone did not affect the time to standing (P=0.49), nor did they alter post-
immobilization behavior; the impala showed normal coordinated movements, social 
behavior and normal appetite after the use of these drugs. Earlier injection with 
DMSO (59±25 s) and pimozide (38±19 s) also did not affect the time to standing 
(F=2.4, P=0.12). DMSO did not alter post-immobilization behavior, but pimozide 
caused incessant restlessness and hyperactivity (akathisia), uncontrolled mouth 
movements (tardive dyskinesia), a stiff gait and a tucked-under stance with muscle 
tremors (parkinsonism) in some of the animals.  
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Figure 1. Mean±SD change in arterial partial pressure of oxygen (A), arterial partial 
pressure of carbon dioxide (B) and alveolar arterial oxygen partial pressure gradient 
(C), in impala immobilized with etorphine, in response to injection (time = 0) I.V.  of 
injectable water (n=10), doxapram (1 mg/kg, n=6), metoclopramide (10 mg/kg, n=6) 
and buspirone (0.05 mg/kg, n=8). a, P<0.05 doxapram vs. water, b, P<0.05  
metoclopramide vs. water and c, P<0.05 buspirone vs. water (one-way ANOVA with 
post-hoc SNK test).
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Figure 2. Mean±SD change in respiratory rate (A), ventilation (B) and tidal volume 
(C), in impala immobilized with etorphine, in response to injection (time = 0) I.V. with 
injectable water (n=10), doxapram (1 mg/kg, n=6), metoclopramide (10 mg/kg, n=6) 
and buspirone (0.05 mg/kg, n= ). a, P<0.05 doxapram vs. water and b, P<0.05  
metoclopramide vs. water (one-way ANOVA with post-hoc SNK test). 
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Figure 3. Mean±SD change in the percentage of peripheral haemoglobin oxygen 
saturation (A) and median movements (B), in impala immobilized with etorphine, in 
response to injection (time = 0) I.V. with injectable water (n = 10), doxapram (1 
mg.kg-1, n = 6), metoclopramide (10 mg/kg, n=6) and buspirone (0.05 mg/kg, n=8). a, 
P<0.05 doxapram vs. water and b, P<0.05  metoclopramide vs. water (one-way 
ANOVA with post-hoc SNK test for O2 saturation changes and Kruskal-Wallis test 
with post-hoc Dunn’s multiple comparison test for changes in movement).  
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Figure 4. Mean±SD change in arterial partial pressure of oxygen (A), respiratory rate 
(B) and ventilation (C), in impala immobilized with etorphine, in response to injection 
(time = 0) I.V. with injectable water (n=10), DMSO (n=5) and pimozide (1 mg.kg-1, 
n=8). a, P<0.05 DMSO vs. water and b, P<0.05  pimozide vs. water (one-way 
ANOVA with post-hoc SNK test). 
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DISCUSSION 
We have shown that the opioid-induced hypoxia that occurs during chemical 
immobilization of a wild antelope can be partially reversed by administration of drugs 
that have serotonergic actions and which currently are available to veterinarians. At a 
dose at which it immobilized our impala, the opioid etorphine caused respiratory 
depression. Hypoxia was the most severe in the first seven minutes of recording (that 
is, up to 15 min after darting), but the respiratory variables gradually improved over 
time. However, the animals still remained clinically hypoxic (PaO2 < 60mmHg, 
percentage peripheral haemoglobin oxygen saturation < 85%) up until the end of the 
immobilization. Metoclopramide and buspirone improved the respiratory function of 
the impala such that PaO2 levels increased within the first three minutes after injection. 
These two drugs, which act at different 5-HT receptors, both appeared to attenuate 
hypoxia by improving oxygen exchange in the lungs, as indicated by the decrease in 
the differences between alveolar and arterial partial pressures of oxygen (Fig. 1C), 
presumably by improving ventilation-perfusion ratios. Although neither drug 
measurably improved minute ventilation, it appeared that metoclopramide did exert 
some effects on respiratory control, as it initially increased respiratory rate (Fig. 2A). 
This increase in respiratory rate, however, was accompanied by a decrease in tidal 
volume, such that minute ventilation did not increase and PaCO2 levels remained 
elevated (Fig. 2 and 1B).  
Like metoclopramide, pimozide also did not improve minute ventilation but it 
did increase respiratory rate (Fig. 4). However, these effects on respiratory rate did 
not appear to result from any pharmacological activity of pimozide on central 
respiratory control, but rather were effects of injecting its solvent DMSO; DMSO 
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alone increased respiratory rate (Fig. 4B) to a greater extent than when pimozide was 
dissolved in DMSO. 
The respiratory effects of doxapram, the standard drug used by veterinarians to 
reverse respiratory depression in animals, were similar to those of metoclopramide 
and buspirone (Fig. 1 and 2). However, doxapram increased minute ventilation over 
the first three minutes of immobilization, but this increase was not accompanied by a 
decrease in PaCO2 at 3 min. The disparity may have arisen because the effects of 
doxapram on minute ventilation were confined to an acute spike that occurred in the 
first minute after its injection (Fig. 2B). The respiratory effects of metoclopramide 
and buspirone essentially did not differ to those of doxapram, except that 
metoclopramide decreased the tidal volume and buspirone led to a smaller increase in 
the respiratory exchange ratio.   
Both metoclopramide and buspirone improved respiratory function in impala 
immobilized with etorphine without reversing catatonic immobilization, a necessity if 
the agents are to be used to improve respiration during chemical immobilization of 
wild animals. However, metoclopramide caused some arousal, evident as more body 
movement during the immobilization (Fig. 3B). This arousal appeared not to be in 
phase with the changes in respiratory function (compare Fig. 3B to Fig. 1, 2) and was 
no different to the arousal and subsequent movements that followed doxapram 
injection. Thus we have shown that administration of the clinically-available drugs 
metoclopramide and buspirone, which have serotonergic effects, improved the 
respiratory status of opioid-immobilized impala, apparently predominantly by 
improving ventilation-perfusion ratios, without reversing catatonic immobilization.  
Buspirone had little effect on the impala’s minute ventilation, a finding similar 
to that seen in humans after oral doses of buspirone (Oertel et al., 2007). However, 
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buspirone improved arterial blood oxygenation, presumably via an improvement of 
the ventilation-perfusion ratio, a finding similar to that observed in immobilized goats 
which received the 5-HT1A agonist 8-OH-DPAT (Meyer et al., 2006). In goats, this 
effect was believed to be brought about by 8-OH-DPAT’s activation of 5-HT7 
receptors (Meyer et al., 2006). However, because buspirone has very little 5-HT7 
activity (Pittalà et al., 2007) we speculate that pulmonary perfusion was improved by 
decreasing pulmonary sympathetic tone via the activation of 5-HT1A receptors in the 
central nervous system (Dabiré et al., 1990; Saxena and Villalón, 1990; Zwieten, 1996; 
Ootsuka and Blessing, 2003). We believe that our impala had high sympathetic 
activity, and hence pulmonary vasoconstriction (Kadowitz and Hyman, 1973; Lumb, 
2005), because of the stress of capture (Meltzer and Kock, 2006), the pharmacological 
effects of etorphine (Roquebert and Delgoulet, 1988), and the associated hypoxia and 
hypercapnia caused by etorphine-induced respiratory depression (Heard et al., 1990; 
Heard et al., 1996). Further evidence that the 5-HT7 receptors may not be involved in 
pulmonary perfusion is that the 5-HT7 agonist pimozide did not improve the A-a 
gradient or arterial blood oxygenation in our impala. Also, contrary to what we might 
have expected given the ability of 5-HT7 activation to restore normal neuronal activity 
in opioid-induced apnea in rats (Richter et al., 2003), pimozide did not increase 
respiratory rate compared to its solvent, DMSO. Metoclopramide also increased 
arterial blood oxygen concentrations apparently also by improving the ventilation-
perfusion ratios, and not by improving minute ventilation. Like the beneficial effect of 
buspirone, that of metoclopramide might be attributable to an increase in pulmonary 
perfusion, because 5-HT4 agonists cause potent venodilation in ruminant pulmonary 
veins (Cocks and Arnold, 1992; Morcillo and Cortijo, 1999).  
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In summary, we have shown that readily available pharmaceutical agents 
(metoclopramide and buspirone) with serotonergic actions can be used to improve 
blood oxygenation in animals with opioid-induced respiratory depression and 
hypoxaemia. Although these agents did not completely resolve the hypoxaemia, and 
although there may be other better ways of  improving blood oxygenation (i.e., using 
oxygen insufflation), our findings have a significant potential practical importance 
considering that these agents, and other more receptor specific serotonin ligands, may 
be included in a dart where they would have their effects in the period immediately 
after the animals become recumbent, a period when the respiratory depressant effects 
of the opioids are most severe and often at a time when a veterinarian is yet to attend 
to the animal. Our data show that serotonergic ligands can partially improve but 
cannot eliminate opioid-induced hypoxia, and thus there exists further opportunity to 
improve respiratory function and blood oxygenation in animals under opioid 
immobilization. We believe that efforts to do so should focus not only on improving 
ventilation but also on further improving pulmonary perfusion and ventilation-
perfusion ratios. 
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Ungulates are genetically programmed to react to any form of danger in a manner that 
both psychologically and physiologically prepares them to escape. In nature, their 
danger usually is in the form of a predator attack, and usually exposure to this danger 
is short-lived, either because it is fatal or an animal escapes. However, during capture 
procedures not only is the danger novel, and most likely very threatening, but it also is 
prolonged over a duration that often is longer than natural fleeing times. Therefore, 
the psychological and physiological reaction to capture may be excessive, and the 
capture most likely causes one of the most challenging episodes that could occur in a 
wild ungulate’s life.     
 
In the past very crude methods were used to capture wild animals; often these were 
centred on trapping, handling animals while they were conscious, and chasing animals 
to exhaustion (Harthoorn 1976; McKenzie 1993). These methods resulted in a high 
incident of mortalities. Over the past few decades capture procedures have been 
refined and new techniques have been introduced so as to reduce mortalities. One of 
the major advances in game capture took place in the 1960’s with the introduction and 
use of highly potent opioid drugs, which induce a rapid reversible catatonic 
immobilization when small volumes of drugs are used in a dart (McKenzie 1993). 
This advance allowed for the reduction of fleeing times and reduced the number of 
animal mortalities during capture operations (Kock et al. 2006; Swan 1993a). 
However, chemical capture of animals is costly and impractical when large numbers 
of animals need to be captured. Therefore mass capture techniques for capturing large 
numbers of animals without the use of capture drugs were developed. Over time these 
techniques have been advanced and refined, and the introduction of long-acting 
neuroleptics, which are given to animals post captu
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stress and also the incidence of capture myopathy (Ebedes et al. 1996; McKenzie 
1993). However, even though these advances have improved capture procedures, and 
reduced mortality rates, significant morbidity and mortality still occurs. In the 
research for my thesis, I endeavoured to gain a better understanding of some of the 
effects of capture on ungulates and to determine whether novel approaches could be 
used to reduce or reverse some of these capture-related side-effects. 
   
Although the topics of my thesis, capture-induced hyperthermia and opioid-induced 
respiratory depression, are distinct, both can occur in capture procedures, and both 
cause a negative oxygen balance which causes an animal to metabolize anaerobically. 
Because anaerobic metabolism of a prolonged duration may be harmful and lethal to 
an animal, I focused on improving the understanding of capture-induced hyperthermia, 
the effects of opioids on respiratory function and pulmonary performance, and the 
treatment of opioid-induced respiratory depression. Currently, the physiological 
responses during capture are not well understood because few continuous and 
accurate measurements of physiological variables have been made. Therefore  
I focused on accurately measuring body temperature and cardiorespiratory variables 
before, during and after capture procedures. 
 
The primary cause of capture-induced hyperthermia is not known, and in the past, it 
has been difficult to determine because it was impossible to continuously measure 
body temperatures in free-living wild animals before, during and after capture 
procedures. To better understand the cause of capture-induced hyperthermia I 
implanted temperature sensitive data loggers which continuously recorded body 
temperatures in wild impala (Chapter 2 & 3). To determine whether capture drugs 
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play a role in capture-induced hyperthermia, impala were captured with and without 
immobilizing drugs (Chapter 2). The role of capture drugs was assessed further in 
Chapter 3 where different pharmacological combinations of drugs were used to 
capture impala. In Chapter 2 and 3 environmental conditions were measured to 
determine whether they influenced capture-induced hyperthermia. In chapter 2 
activity levels in both chemically and net captured impala were assessed to determine 
whether activity plays a role in capture-induced hyperthermia. The role of stress in 
capture-induced hyperthermia also was assessed in Chapter 2 and 3 by measuring 
cortisol levels in captured animals. To further assess the role of stress, impala were 
habituated to boma housing and handling (Chapter 2). Chapter 3 also examined the 
interaction between chemical immobilization, capture-induced hyperthermia and 
opioid-induced respiratory depression.   
 
It is known that opioids cause respiratory depression and hypoxia when wild animals 
are immobilized chemically. These effects have been attributed primarily to a 
depression in respiratory rate and pulmonary ventilation (Pattinson 2008; Santiago & 
Edelman 1985), leading to the conclusion that the best treatment of this depression is 
to partially reverse the opioids’ effects or administer drugs that improve ventilation 
(Meltzer & Kock 2006a; Swan 1993b). However, unlike in humans, very little is 
known about the effects of opioids on cardiopulmonary performance in wild animals. 
Furthermore, the reversal agents that currently are used to treat opioid-induced 
respiratory depression generally also reverse the immobilizing effects of the opioids, 
and so are unsuitable for use in capture. Recently, there has been a novel suggestion 
to use serotonergic ligands to reverse opioid-induced respiratory depression. However, 
this suggestion has been based on the effects of serotonergic ligands on neuronal 
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function in the respiratory network rather than the effects of these ligands on 
cardiopulmonary function and performance, and the crucial blood gas variables. To 
determine whether serotonergic ligands could be used to reverse opioid-induced 
respiratory depression during chemical immobilization, I used goats in a laboratory 
setting (Chapter 4). In these goats I measured blood gases and other cardiopulmonary 
variables to determine the effects of opioids and serotonergic ligands on 
cardiopulmonary function and performance. Following this study, I conducted a 
similar study in the field, in wild chemically immobilized impala, to determine if 
commercially-available serotonergic ligands could be used to reverse opioid-induced 
respiratory depression (Chapter 5). 
 
The work described in my thesis has yielded important new insights, I believe, into 
the primary cause of capture-induced hyperthermia, and the role of physical exercise, 
ambient conditions, and drugs in this hyperthermia. It also has shown that the hypoxia 
caused by opioids is not caused solely by the depressant effects of opioids on 
respiratory rhythm and pulmonary ventilation but also, and perhaps more importantly 
by their effects on pulmonary perfusion and gas exchange. Moreover, I have shown 
that serotonergic ligands can be used to reverse opioid-induced respiratory depression 
and that their effects improve not only respiratory rhythm but also oxygen exchange 
in the lungs. 
 
6.1  Reduction of capture-induced hyperthermia 
Wild animals typically develop hyperthermia when captured (Cheney & Hattingh 
1987; Gericke et al. 1978; Hofmeyr et al. 1973; Kock et al. 1987a; Kock et al. 1987b; 
Martucci et al. 1992; Montané et al. 2003; Montané et al. 2007). The nature of this 
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hyperthermia is that body temperature rises rapidly from the onset of capture and may 
continue to rise for up to 30 minutes after capture, before declining. Body temperature 
often exceeds 41-42˚C, the temperature at which cellular damage starts to occur in 
most mammals (Grint et al. 2007; Haskins 1995). Because of the nature and 
magnitude of these hyperthermias, the causes and consequences of capture-induced 
hyperthermia have been equated to those of heat stroke; heat stroke is considered a 
potential diagnosis when an animal’s body temperature has exceeded 40-41˚C 
(Bouchama & Knochel 2002; Leon 2006; Yan et al. 2006). Heat stroke occurs when 
the body’s normal ability to regulate temperature is overwhelmed by prolonged 
exposure to heat, with (exertional heat stroke) or without strenuous exercise (classic 
heat stroke; Bouchama & Knochel 2002; Leon 2006).  
 
Although capture-induced hyperthermia may share some similarities with heat stroke, 
it occurs through different mechanisms. Capture-induced hyperthermia, for example, 
occurs irrespective of the environmental conditions, and even when animals are 
captured in the cold (Montané et al. 2003; Montané et al. 2007). As I have shown 
(Chapter 2 and 3), the magnitude of capture-induced hyperthermia is not correlated to 
environmental conditions at the time of capture, a situation different to that prevailing 
in heat stroke. However, it is likely that environmental conditions play an important 
role post-capture, as they will determine how easily an animal will lose excessive 
body heat to the environment. Additionally, immobilizing agents which alter an 
animal’s ability to thermoregulate may result in environmental conditions influencing 
body temperature. 
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As for environmental conditions, activity also does not appear to be correlated with 
the magnitude of capture-induced hyperthermia (Chapter 2), a situation contrary to 
that of exertional heat stroke. There is no doubt, however, that the metabolic heat that 
is generated from active muscles will contribute to capture-induced hyperthermia, but 
its overall contribution may be small (Bakken et al. 1999), especially if exercise 
duration and intensity is limited during capture procedures. Even if exercise intensity 
was high, or extended over a long duration, hyperthermia may be small because under 
natural circumstances animals dissipate heat effectively and rarely experience more 
than 1-2°C rises in body temperature during exercise. If an animal severely exerts 
itself, a situation which would not occur naturally unless an animal were to be chased 
by a predator or captor, it is likely that a large proportion of heat gained could be 
attributed to muscle activity. However, without the influence of stress, normal heat 
loss mechanisms would limit the hyperthermia, or an animal would fatigue before 
body temperatures reach lethal limits (Jessen 2001). Furthermore, we observed 
precipitous rises in body temperature in captured animals that did not engage in 
strenuous exercise, and also found that animals that were chased vigorously, but were 
not captured, had hyperthermias of smaller magnitude than when they were captured 
(Chapter 2). Therefore, activity also does not appear to be the primary cause of 
capture-induced hyperthermia.   
 
Previously it has been suggested that capture-induced hyperthermia and capture 
myopathy are in essence attributable to the same biochemical malfunction as Porcine 
Stress Syndrome (Mitchell & Heffron 1982). Although pigs that suffer from Porcine 
Stress Syndrome develop an acute precipitous rise in body temperature similar to that 
of capture-induced hyperthermia, this hyperthermia is not easily reversed and is 
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associated with a genetic predisposition to stress, which results in aberrant 
metabolism. Additionally, these pigs are genetically predisposed to developing 
malignant hyperthermia (Mitchell & Heffron 1980; 1982). Capture-induced 
hyperthermia, on the other hand, can be reversed easily, and it appears not to be the 
result of malignant hyperthermia, as it occurs when animals are captured with or 
without exercise, and with or without drugs, and the drugs that are used have not been 
shown to cause malignant hyperthermia (Chapter 2 and 3). Furthermore, malignant 
hyperthermia has been shown not to be the cause of capture myopathy (Antognini et 
al. 1996). I also have shown that capture-drugs, with differing effects on 
thermoregulation, do not influence the magnitude of capture-induced hyperthermia 
(Chapter 3). Therefore, the pharmacological properties of capture-drugs also are not 
the primary cause of capture-induced hyperthermia. However, these drugs may cause 
thermal lability during chemical immobilization and therefore may play an important 
role in the changes in body temperature post the initial capture and after removal of 
the initial stressor. Therefore, in environments with high heat loads, drug-induced 
thermal lability may compound capture-induced hyperthermia and all efforts should 
be made to reduce heat gain in immobilized animals, thereby reducing the 
complications associated with capture-induced hyperthermia.  
 
I believe that the major factor contributing to the magnitude of capture-induced 
hyperthermia is stress. I have shown that individual animals react differently to 
capture and that their differing stress levels can be correlated to the magnitude of the 
hyperthermia that they develop (Chapter 2 and 3). I have also shown that if animals 
are habituated to handling, capture and boma housing, their stress response and 
capture-induced hyperthermia becomes blunted (Chapter 2). In addition, stress 
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appears to be the only possible explanation for the precipitous rises in body 
temperature seen in animals captured in confinement where activity levels and 
environmental heat loads were low (chapter 2). Also, the stress of handling conscious 
net-captured animals causes a larger hyperthermia than that caused by high intensity 
exercise before net-capture (chapter 2). Furthermore, although not describe in the 
publications of this thesis, I have noticed similar hyperthermias in impala which were 
disturbed by the presence of humans but were not chased or captured; similar 
disturbance-induced hyperthermias have been documented in wild penguins (Regel & 
Putz 1997). Therefore, I concluded that the primary cause of capture-induced 
hyperthermia is stress, and I propose that the magnitude of this stress-induced 
hyperthermia exceeds that of exercise-induced and probably all other hyperthermias 
that may occur during capture.  
 
Although stress is the predominant cause of capture-induced hyperthermia, it is still 
unclear what the mechanisms are that cause the increase in heat production in stress-
induced hyperthermia. Therefore, until such time that these mechanisms are 
understood, and alternative approaches can be proposed, the best method of reducing 
capture-induced hyperthermia is to reduce stressful stimuli and the perception of 
stress during capture procedures.  
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6.2  Opioid-induced respiratory depression and its reversal 
Opioid-induced respiratory depression is a common adverse event that occurs when 
wild animals are immobilized chemically (McKenzie 1993; Meltzer & Kock 2006b). 
The primary signs of opioid-induced respiratory depression are believed widely to be 
brought about by the depressive effects of opioids on respiratory neuronal function, 
which results in a depression in rhythmogenesis and pulmonary ventilation 
(McCrimmon & Alheid 2003; Pattinson 2008; Santiago & Edelman 1985), in turn 
causing hypoxia and hypercapnea (Lumb 2005). In my chemically immobilized goats 
and impala, I found that the opioid etorphine caused hypoxia and hypercapnea 
(Chapter 4 and 5). However, the partial pressures of oxygen were not indicative of a 
pure hypoventilation, but also were related to a decrease in transmembranal oxygen 
exchange, as revealed by an increase in the gradient of the partial pressures of oxygen 
between the alveoli and arterial blood (A-a gradient). I assumed that the decrease in 
oxygen exchange was brought about by a ventilation perfusion mismatching, caused 
predominantly by a decrease in pulmonary perfusion. Although I did not measure 
pulmonary blood flows or pressures, my assumptions were based on the findings that 
etorphine causes pulmonary vasoconstriction (Heard et al. 1996) and chemical 
immobilization causes systemic sympathetic activation (Meltzer & Kock 2006b; 
Roquebert & Delgoulet 1988).  
 
As expected, most of the serotonergic ligands that I tested in goats and impala 
improved opioid-induced depression of respiratory rhythmogenesis, a finding similar 
to that in rats (Manzke et al. 2003; Richter et al. 2003; Sahibzada et al. 2000). This 
improvement in rhythmogenesis increased respiratory rate, but it did not necessarily 
improve ventilation. In goats (Chapter 4) I found that the distinct rhythmogenic 
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effects of the 5-HT1A and 5-HT7 agonists 8-OH-DPAT had no effect on ventilation, as 
the PaCO2 remained elevated, but it did improve the PaO2 through improving oxygen 
exchange. Initially I speculated that the improvement of oxygen exchange was 
brought about by 8-OH-DPAT’s actions on 5-HT7 receptors in the pulmonary 
vasculature, which would have caused vasodilatation (Morecroft & MacLean 1998). 
However, in impala (Chapter 5), when I tested buspirone, which does not activate 5-
HT7 receptors, but is an agonist at 5-HT1A receptors, oxygen exchange also was 
improved. In addition, I found that pimozide (Chapter 5), an agonist of 5-HT7 
receptors, did not improve oxygen exchange or the PaO2, and nor did it improve 
rhythmogenesis as previously suggested for rats treated with 8-OH-DPAT (Richter et 
al. 2003). Therefore I conclude that the beneficial effects of the 5-HT1A agonists 8-
OH-DPAT and buspirone during chemical immobilization are not through their 
rhythmogenic effects but rather through their effects on pulmonary blood flow, which 
I believe is brought about by their ability to reduce sympathetic tone (Blessing 2004; 
Dabiré et al. 1990; Ootsuka & Blessing 2003; Saxena & Villalón 1990; Zwieten 1996).  
 
The 5-HT4 agonist zacopride did improve ventilation; it decreased the PaCO2 in 
chemically immobilized goats (Chapter 4). It also improved oxygen exchange, an 
effect which most likely can be attributed to 5-HT4-induced venodilation in the 
pulmonary vasculature (Cocks & Arnold 1992). In impala (Chapter 5), the 5-HT4 
agonist metoclopramide also improved oxygen exchange and the PaO2, but it did not 
improve ventilation. Therefore the beneficial effects of 5-HT4 agonists are similar to 
those of the 5-HT1A agonists in that they improve oxygen exchange, but depending on 
the agonist, or the species it is used in, they also may have the added advantage of 
improving ventilation.  
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Importantly, neither the 5-HT4 or 5-HT1A agonists reversed the immobilizing effects 
of the opioid etorphine. Furthermore, as shown in chapter 4, if they are combined with 
the opioid, they have the added benefit of reducing the time that the animals take to 
become recumbent, an effect that could be attributed to serotonin’s role in catatonia, 
catalepsy and motility (Broekkamp et al. 1988; Costall & Naylor 1975). The decrease 
in time to recumbency is not only important in making capture operations more 
efficient, but is vital, as shown in chapter 3, in reducing the animal’s exposure to a 
stressor, and subsequently reducing the magnitude of the capture-induced 
hyperthermia, thus further reducing metabolism and further oxygen demand.   
 
6.3      Recommendations and conclusions 
Although stress-induced hyperthermia is a well documented occurrence, little is 
known about the mechanisms involved in its generation (Oka et al. 2001; Olivier et al. 
2003; Vinkers et al. 2008). Because stress is a major factor in capture-induced 
hyperthermia, I believe that stress-induced hyperthermia is a major component of 
capture-induced hyperthermia. Therefore, gaining a better understanding of the 
mechanisms involved in stress-induced hyperthermia may help future attempts at 
limiting capture-induced hyperthermia.  
 
At present, what is known about stress-induced hyperthermia is that anxiolytic drugs 
reduce or abolish its occurrence in mice (Bouwknecht et al. 2007; Olivier et al. 2003; 
Vinkers et al. 2008). Anxiolytics which have 5-HT1A agonist effects primarily have 
been shown to antagonise stress-induced hyperthermia in rodents (Lecci et al. 1990; 
Ootsuka & Blessing 2003). These anxiolytics may be important agents to include in a 
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cocktail of drugs used to dart an animal as they may reduce capture-induced 
hyperthermia and at the same time improve blood oxygen levels. Other anxiolytics 
that antagonise stress-induced hyperthermia, and which have not been tested for this 
purpose in ungulates, are the benzodiazepines and α1-adrenoreceptor antagonists 
(Bouwknecht et al. 2007; Oka et al. 2001; Olivier et al. 2003). It is also worth noting 
that α2-adrenoreceptor agonists and D2-antagonists, which are classes of drugs 
commonly used as sedatives and tranquilizers during capture, do not antagonise 
stress-induced hyperthermia (Bouwknecht et al. 2007; Olivier et al. 2003). Similarly, 
opioids and their antagonists also are not effective, and neither are anti-pyretics 
(Bouwknecht et al. 2007; Olivier et al. 2003; Vinkers et al. 2009; Vinkers et al. 2008). 
 
In addition to little being known about the mechanisms involved in the generation of 
stress-induced hyperthermia, little is known about the effects of capture-induced 
hyperthermia on an animal. Currently most deaths post-capture are attributed to 
capture myopathy and although hyperthermia has been implicated as contributing to 
the pathology of capture myopathy (Antognini et al. 1996; Cheney & Hattingh 1987; 
Gericke et al. 1978; Meltzer & Kock 2006b), its role needs to be elucidated. If deaths 
post-capture are attributed, by default, to capture myopathy, other pathologies related 
to hyperthermia may be missed and the importance of treating or preventing 
hyperthermia may be overlooked. For example, hyperthermia may induce other lethal 
pathologies like endotoxic shock and a systemic inflammatory response which may 
lead to multiple organ dysfunction (Bouchama & Knochel 2002; Leon 2006; Yan et al. 
2006). Furthermore, anorexia and the inability to adapt to new environments post-
capture, which is a major concern in some species, especially white rhino in bomas 
(McKenzie 1993), may have its origins in the capture process where hyperthermia 
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may cause gastrointestinal damage with subsequent endotoxaemia and cytokine 
release (Leon 2006; 2007). This process is known to cause a post-hyperthermic fever 
(Leon 2006; 2007) and sickness behaviour which will result in anorexia and 
depression (Maier & Watkins 1999). Therefore, future studies should investigate the 
effects of hyperthermia during and after capture, and effective treatments of 
hyperthermia should be established. 
 
Future studies should also investigate the treatment of the other systemic adverse 
effects of hyperthermia and stress. A consequence that I have not investigated in my 
thesis, but which also is of utmost importance, is the acidotic effect of hypoventilation 
and stress-induced and hyperthermia-induced anaerobic metabolism. Acidaemia has 
been implicated in causing per-acute deaths during capture, as it causes 
hyperkalaemia and myocardial dysfunction (Harthoorn 1976). Acidaemia has also 
been implicated in causing pulmonary hypertension (Harthoorn & Young 1976). 
Although bicarbonate treatment normalises potassium concentrations (Gericke & 
Belonje 1975), decreases pulmonary hypertension (Harthoorn & Young 1976), and 
reduces mortality (Harthoorn et al. 1974; Harthoorn & Young 1976), currently it is 
not often used post-capture. Therefore future studies should also readdress the 
treatment of acidaemia.  
 
An increasingly common practice in the field is to administer or insufflate oxygen to 
chemically immobilized animals that exhibit opioid-induced respiratory depression 
(Bush et al. 2004; Kock et al. 2006). Essentially this practice corrects hypoxia, but it 
also may be helpful at reducing anaerobic metabolism and metabolic acidosis in 
hyperthermic and stressed animals. Although oxygen supplementation and 
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insufflation may reduce metabolic acidosis, it will not correct respiratory acidosis, but 
it may compound it by reducing hypoxic respiratory drive and ventilation (Paterson et 
al. 2009). Another disadvantage is that it can be applied to an animal only once an 
animal is fully immobilized and an oxygen cylinder is available at the animal’s side. 
Oxygen cylinders are cumbersome in the field, especially if more than one cylinder is 
needed. Therefore, although it is helpful, it is not always practical to administer or 
insufflate oxygen to animals with hyperthermia or respiratory depression. 
Additionally, I have found that respiratory depression is most severe directly after an 
animal becomes recumbent, at a time when humans, and oxygen cylinders, are not yet 
at an animal’s side. Therefore, it would be ideal to have a drug that could be 
incorporated in a dart that would reduce capture-induced hyperthermia and prevent 
respiratory depression. I believe that serotonergic ligands have the potential to fulfil 
both these requirements. Serotonin not only plays a major role in the control of body 
temperature (Bligh 1979; Cremer & Bligh 1969), but as I have already mentioned, 
some of the anxiolytic serotonergics have the ability to antagonise stress-induced 
hyperthermia. Furthermore, serotonergic ligands also appear to enhance the ability of 
the opioid drugs to immobilize the animal rapidly, i.e. shorten the “knock down” time.    
 
Contrary to what previous investigators may have assumed, as I have found, the 
positive rhythmogenic effects of the serotonergic ligands do not necessarily translate 
into an improvement of ventilation. My research did not reveal why not. It may be 
that the ligands that I used were not all that specific for the target receptor or may not 
have been potent enough. It could also be that the positioning of the animal, and the 
catatonic effects of the opioids, limited the depth of breathing. However, what is clear 
is that the ligands that I used did have an important effect on pulmonary performance 
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and they did improve blood oxygenation by improving transmembrane oxygen 
exchange. Improvement of oxygen exchange, presumably by improving pulmonary 
perfusion, may be the most important way of correcting blood oxygen pressures 
during chemical immobilization, and any other procedure where opioids are used. The 
serotonergic ligands that I used did not entirely restore the A-a gradients, so it appears 
that there is further scope to improve pulmonary perfusion and oxygen exchange. 
However, it is essential to first establish what the mechanisms are that cause this 
reduction in pulmonary perfusion. Currently we know that immobilizing opioids 
cause pulmonary hypertension (Heard et al. 1996) but how they have this effect is not 
known. In some species, the effect is mediated by opioid-induced release of histamine 
(Hakim et al. 1992), but this effect does not occur in all species (Lumb 2005). 
Another important cause of pulmonary hypertension, especially during capture, could 
be related to the activation of the sympathetic nervous system (Harthoorn & Young 
1976; Heard et al. 1996). Opioids too may have a direct effect on the pulmonary 
vasculature, or may cause indirect vasoconstriction by causing localized hypoxic-
induced pulmonary vasoconstriction. Once the mechanism is established, future 
investigations should determine whether blood oxygenation can be further enhanced 
by further improving pulmonary perfusion. Furthermore, it is also important to 
determine whether agents that improve ventilation and oxygen exchange also improve 
tissue perfusion and tissue oxygenation. These effects may be particularly important 
in muscle, the organ primarily affected during capture (Harthoorn 1976).  
 
To conclude, I have shown that capture-induced hyperthermia is caused 
predominantly by stress rather than by the effects of physical activity, environmental 
conditions, or the pharmacological effects of the capture drugs. I suggest that limiting 
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the magnitude and duration of this hyperthermia requires minimising the time an 
animal is exposed to a stressor, i.e., the time from first encounter until the animal 
becomes sedated and chemically immobile or confined. If animals are not 
immobilized but are confined in a foreign environment, steps should be taken to 
reduce further exposure to stressors. If animals are chased before capture, steps also 
should be taken to limit additional heat production by decreasing the length, duration 
and especially the intensity of pre-capture exercise. Restricting capture to cool times 
of the day, or cool months of the year, will not protect animals from developing 
capture-induced hyperthermia; contrary to the folk lore amongst capture teams. To 
reduce capture-induced hyperthermia, and its associated morbidity and mortality, 
capture techniques that invoke lower stress responses should be used. Additionally, 
the pharmacology of the drugs that are used to capture animals, if they do not have 
anxiolytic effects, will not directly influence capture-induced hyperthermia, but drug 
cocktails should be selected so as to restrict time and distances to recumbency, 
thereby limiting the stress and metabolic heat production. However, in some species 
the drugs with the best knock down times have the greatest respiratory depressant 
effects, and therefore caution should be exercised when selecting drugs based purely 
on their immobilizing properties.  
 
Therefore, drug cocktails also should be selected following consideration of their 
respiratory depressant effects, and once an animal is immobilized it should be 
monitored to track whether it develops hypoxia. If it does develop hypoxia 
appropriate steps should be taken to reduce this hypoxia. One of these steps would be 
to administer serotonergic ligands which have agonist effects at 5-HT4 and 5-HT1A 
receptors. Although no serotonergic ligands are registered for use in wildlife, the two 
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serotonergic drugs buspirone and metoclopramide, which are available readily for 
clinical use in man and other mammals, could be used off/extra-label. These drugs, 
and the other serotonergic ligands that we tested, have the ability to improve 
respiratory rhythmogenesis but their main beneficial effect was not that of improving 
ventilation but rather of improving oxygen exchange, presumably by improving 
pulmonary perfusion and ventilation perfusion ratios. I believe that the effectiveness 
of these drugs at reversing opioid-induced respiratory depression during chemical 
immobilization will be fully realised when the drugs are included in a dart, so that 
their rhythmogenic effects and their effects on pulmonary perfusion will occur right 
from the onset of chemical immobilization. Additionally, I have shown that 
serotonergic ligands can enhance catatonic immobilization and therefore their use in a 
dart may also improve “knock down” times, thereby reducing stress and capture-
induced hyperthermia. However, future studies will need to investigate this action 
further.  
 
Although I have shown that serotonergic ligands can partially improve opioid-induced 
hypoxia, they did not eliminate it, so there exists a large scope to further improve 
respiratory function and blood oxygenation in animals under opioid immobilization. I 
believe that efforts to do so should focus not only on improving ventilation but also 
on further improving pulmonary perfusion and ventilation-perfusion ratios. These 
effects and other efforts to reduce capture-induced hyperthermia hopefully will reduce 
the morbidity and mortality associated with capture. 
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